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Cell-to-cell variability in clonal populations is reflected in a distribution of mRNA and 
protein levels among individual cells, including those of key transcription factors 
governing embryonic stem cell (ESC) pluripotency and differentiation. This may be a 
source of heterogeneity resulting in mixtures of cell types in differentiated populations 
despite efforts to control the differentiation conditions and the use of a clonal starting 
population. In addition, this distribution may be affected by the cell microenvironment 
during self-renewal. Prior studies on self-renewal culture of ESC, however, focused on 
long term proliferation and pluripotency. The effects of culture conditions during self-
renewal on the effectiveness of subsequent differentiation protocols remains 
understudied. 
 
Using a mouse ESC line harboring a GFP reporter, we examined cell-to-cell variability 
in clonal undifferentiated populations and how such variability affects subsequent 
differentiation. Subpopulations sorted according to their levels of Oct4-GFP expression 
displayed distinctly different expression levels of pluripotency and early differentiation 
markers and differentiated into cardiomyocytes at different efficiencies. However, when 
allowed to self-renew after sorting, the subpopulations regenerated the parental 
distributions of Oct4-GFP and subsequent differentiation after regeneration did not show 
differences. 
 
In addition to differences between cells in a clonal population, self-renewal conditions 
affecting Oct4 expression on the population-level were examined. Changes in culture 
conditions during self-renewal by low oxygen culture or small molecule dual inhibition (2i) 
of mitogen-activated protein kinase and glycogen synthase kinase reversibly affected 
levels of Oct4 expression in cells that were otherwise pluripotent. Effects of different 
self-renewal conditions immediately preceding differentiation are manifested by 
changes in subsequent differentiation to cardiomyocytes. 
 
This study demonstrates that manipulation of self-renewal culture conditions can lead to 
changes in the outcomes of defined differentiation protocols, a novel dimension to 
explore for directed differentiation of pluripotent stem cells.  
 
Thesis Supervisor: Clark K. Colton 
Title: Professor of Chemical Engineering 
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Chapter 1 Introduction 
 
1.1 Pluripotent stem cells 
First isolated from mouse [1], then more recently human blastocysts [2], pluripotent 
embryonic stem cells (ESC) have the ability to self-renew in the undifferentiated state 
indefinitely and differentiate into all cell types of the adult organism. They hold immense 
clinical and research potential for drug screening, disease modeling, as a model to 
study mammalian development, and to generate replacement cells for application in 
regenerative medicine [3–9]. Cardiomyocytes [10], bone marrow [11], dopamine 
neurons [12], and β-cells [13] have been differentiated from ESC as potential therapies 
for cardiac infarctions, leukemia, Parkinson’s disease, and diabetes respectively. Other 
studies have also demonstrated the ability to generate self-organized tissues [14] and to 
perform gene and cell therapy using ESC [15].  
 
The discovery of another source of pluripotent cells, induced pluripotent stem cells 
(iPSC) [16–18] gave further hope for personalized therapies by autologous 
transplantation of cells and tissues differentiated from iPSC derived from the patients 
themselves [19], and for recapitulation of disease development by generating disease 
specific iPSC [20], in addition to all of the potential applications of ESC [21–25]. iPSC 
and ESC have shown similar potential to differentiate into cell types of interest and fulfill 
other criteria for pluripotency [26–28], however, some differences remain [29].  
 
For pluripotent stem cells (PSC) of both types, many obstacles remain before their 
immense potential can be fulfilled. This includes removing the danger of tumorigenicity 
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of residual undifferentiated cells [30], immunogenicity of the transplanted cells [31], the 
development of methods for propagation in their undifferentiated state, and efficient 
protocols for directed differentiation in order to generate sufficient numbers and purities 
of the desired cell types [32].   
 
1.2 Self-renewal and propagation in the pluripotent state 
In order to generate sufficient numbers of cells, PSC can be propagated in their 
undifferentiated state until differentiation is initiated. For mouse ESC (mESC), this is 
usually accomplished by either co-culture on mouse embryonic fibroblasts (MEFs) or 
the addition of leukemia inhibitory factor (LIF) [33], a cytokine which acts by activating 
the JAK-STAT3 pathway [34]. Human ESC (hESC) can be kept in the pluripotent state 
by culture medium supplemented with basic Fibroblast Growth Factor (bFGF) [35] on a 
layer of various feeder cells [36] or an animal-derived protein matrix [37], although 
recently a fully defined self-renewal culture system has been discovered [38]. 
 
The main concern of undifferentiated PSC culture is to ensure the maintenance of the 
pluripotent state and prevent spontaneous differentiation while sustaining normal 
karyotype and cell viability. To do so, it must support the highly complex cellular 
machinery for maintaining pluripotency that is underpinned at its core by three 
pluripotency genes – Oct4, Sox2, and Nanog [39–43]. Disruption of these core 
transcription factors caused spontaneous differentiation of PSC and loss of the 
pluripotent state. 
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An ectopic increase in Oct4 expression in mESC directed spontaneous differentiation 
down the mesodermal lineage [44, 45] while a decrease in Oct4, or increase in Cdx2 
expression relative to Oct4, directed differentiation to trophectoderm [45, 46]. Similar 
behavior occurred in hESC with an ectopic decrease in Oct4 expression resulting in 
spontaneous differentiation to ectoderm and mesoderm, while an ectopic increase 
caused differentiation to endoderm [47]. Both Oct4 and Sox2 determine germ layer fate 
decisions during early differentiation in opposite directions, with Oct4 promoting 
differentiation down the mesodermal and endodermal lineages, while Sox2 promoted 
differentiation down the ectodermal lineage, and each suppressed the promoted lineage 
of the other [48]. Expression of Nanog prevented differentiation, and mESC can exhibit 
transient down-regulation of Nanog expression. This down-regulation has been 
hypothesized to generate a necessary intermediate state between maintaining 
pluripotency and differentiation [49, 50]. In hESC, Nanog affected cell fate choice, with 
an extended expression of Nanog during differentiation leading to increased 
mesendodermal specification [51]. 
 
Recent studies demonstrated that multiple metastable pluripotent states for PSC exist 
as distinct subpopulations within a clonal population. In addition to Nanog, Rex1 [52] 
and Stella [53] are also heterogeneously expressed in mESC. These subpopulations 
were able to reversibly interconvert when the population was kept in conditions 
supporting self-renewal of the pluripotent state. Given that the culture conditions that 
maintain pluripotency can also affect the transition of mESC between the different 
pluripotent states, and that pluripotency factors can specify differentiation to different 
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cell fates [48, 54], it is thus important to assess the effects of the self-renewal conditions 
on PSC and on the efficiency of subsequent differentiation to different lineages. Two 
aspects in particular – culture oxygen levels, and the use of small molecule inhibitors 
supporting undifferentiated culture – are discussed in greater detail in sections 1.5 and 
1.6.  
 
1.3 Directed differentiation 
 
The design of directed differentiation protocols for pluripotent stem cells has employed 
many different strategies to enrich the resulting differentiated population with the 
desired cell type [55, 56]. To direct differentiation to cardiomyocytes from both mouse 
and human PSC [57], for example, protocols have included the use of growth factors 
such as Activin or Nodal and BMP4 [58], the use of small molecules 5-aza-2’-
deoxycytidine [59] or ascorbic acid [60], genetic manipulation to ectopically express a 
cytokine, TNF-α [61], co-culture with a visceral endoderm-like cell line (END-2) [62], or, 
most recently, synthetic mRNA transfection [63]. Combinations of techniques, such as 
the addition of stauprimide with Activin A for directed differentiation to definitive 
endoderm [64], or the step-wise protocol of sorting Flk1+ cells differentiated from 
miPSC, then co-culturing the purified intermediate population on OP9 stroma cells to 
obtain cardiomyocytes [65], have also been documented.  
 
The designs of directed differentiation protocols have grown in sophistication, inspired in 
part by insights from developmental biology. Strict temporal control of the cellular 
microenvironment in order to mimic developmental cues, optimizing concentrations of 
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growth factors (Activin A for example, can induce both endodermal and mesodermal 
specification depending on concentration), and optimizing levels of growth factors 
depending on the stage of differentiation have yielded success [13, 58, 66]. The focus, 
however, has been predominantly on the time period and process during which the cells 
are already differentiating, and much remains unknown about how the culture conditions 
before the initiation of differentiation affects the cells subsequently. This is in spite of the 
many studies (summarized above in section 1.2) showing that pluripotency factors, 
which are highly active when PSCs are in their undifferentiated state, can play roles in 
specifying cell fate during differentiation.    
 
The focus of this thesis is on cell-to-cell variability (population heterogeneity), culture 
oxygen levels, and the use of small molecules during self-renewing culture on 
subsequent differentiation. It examines the relationship between starting undifferentiated 
state of the ESC and the resulting differentiated population, an aspect of self-renewal 
that has not received much attention. Experiments on cell-to-cell variability examine 
differences between clonal undifferentiated cells within a population, while studies 
combining culture oxygen levels and the use of small molecules in self-renewal culture 
examine their effects on self-renewal and the efficiency of subsequent directed 
differentiation of undifferentiated populations as a whole. More detailed treatments of 
these topics follow. 
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1.4 Cell-to-cell variability in clonal undifferentiated PSC populations  
Cell-to-cell variability or cellular heterogeneity in clonal populations has received 
increasing attention with the development of methods to measure characteristics of 
single cells, rather than traditional methods yielding population-averaged results. 
Studies showing heterogeneity in single mammalian cells of a clonal population in 
mRNA [67, 68] and protein levels [69] that can have important biological functions 
suggest that traditional ensemble measurements insufficiently capture the 
characteristics of single cells [70, 71]. 
 
Numerous studies have reported heterogeneity in clonal stem cell populations that 
correlate with differences in subsequent cell fate choice. Hematopoietic stem cells have 
transcriptome-wide differences in subpopulations sorted by expression of a surface 
antigen, Sca-1, despite being clones generated from a single cell [72], and levels of 
Sca-1 correlated to differentiation efficiencies to different cell lineages. Within clonal 
populations of mESC, there were heterogeneities in expression of Nanog [50], Rex1 
[52], and Stella [53], all normally associated with pluripotency, and in an early 
endodermal marker Hex [73]. Subpopulations exhibiting high or low levels of expression 
of these genes exhibited different differentiation proclivities when allowed to differentiate. 
Levels of these genes in mESC allowed to self-renew in the undifferentiated state, 
however, are dynamic, and single cells can switch between high and low levels of 
expression. In both human ESC and iPSC, heterogeneities occurred in mRNA levels of 
multiple genes, although single hiPSC exhibited higher levels of heterogeneity than 
hESC [74]. The multitude of metastable pluripotent states has led to a proposal that 
21 
 
pluripotency is not a set of distinct states, but instead a continuum of states [75]. This 
heterogeneity, however, is viewed as undesirable in directed differentiation protocols 
because it can lead to heterogeneity in the differentiated population, which can be 
detrimental to the production of clinically useful cells and tissues [76]. 
 
Cell-to-cell variability in mRNA expression levels can occur due to gene expression 
noise, arising from transcription occurring in bursts, rather than at a continuous steady 
rate [68, 77, 78]. Together with a positive feedback loop, for example, a gene that 
activates its own transcription, such stochastic gene expression is able to generate 
stable distinct phenotypes [79]. Many theories have been put forward to describe the 
mechanisms behind such cell-to-cell variability, and it has been proposed that the large 
interconnected network of genes and epigenetic states in mammalian systems, together 
with transcriptional noise, create multiple stable gene expression profiles that clonal 
single cells may inhabit [80]. More importantly, as evidenced by effects on subsequent 
differentiation of cells in different “states”, such cell-to-cell variability can have important 
developmental functions.   
 
 
1.5 Effects of oxygen on the undifferentiated phenotype 
 
Adapted and updated from Millman, J.R., J.H. Tan, and C.K. Colton, The effects of low 
oxygen on self-renewal and differentiation of embryonic stem cells. Current Opinions in 
Organ Transplantation, 2009. 14(6): p. 694-700 with permission from Lippincott Williams 
& Wilkins 
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One aspect of the culture microenvironment that has mostly been ignored in 
conventional cell culture is the oxygen partial pressure experienced by the cells. All cells 
of the developing embryo are exposed to oxygen levels in vivo far below that of 
atmospheric levels, and they differentiate and undergo organogenesis in a low oxygen 
environment [81–87]. The local oxygen environment is potentially an important variable 
for manipulation by researchers hoping to recapitulate specific differentiation pathways 
in vitro.  
 
Mammalian cellular responses to oxygen levels are predominantly mediated by Hypoxia 
Inducible Factors (HIFs), a family of heteromeric transcription factors. HIF-α subunits 
are constitutively expressed but are post-translationally regulated through rapid 
degradation in the presence of oxygen levels higher than 5% [88–90].  The HIF-1β 
subunit (also known as the aryl hydrocarbon receptor nuclear translocator or ARNT) is 
oxygen insensitive, but is only active as a transcription factor when dimerized with the 
appropriate stabilized HIF-α subunit under sufficient cellular hypoxia. The mammalian 
hypoxic response includes up-regulation of a large number of genes, including the 
vascular endothelial growth factor (VEGF), the adipose differentiation related protein 
(ADRP), and RTP801, which is known to be regulated in development, amongst others 
[91].  
 
1.5.1 Derivation of new embryonic stem cell lines 
Derivation of new ES cell lines, both mouse [92, 93] and human [38, 94], benefit from 
being performed in low oxygen levels. Studies examining the establishment of new ES 
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cell lines from blastocysts under 5% oxygen have had greater success than under the 
20% more commonly used. The benefits of low oxygen conditions included an increase 
in the number of individual colonies exhibiting alkaline phosphatase activity [93], an 
increase in the number of proliferating cells [92], and removal of the need for undefined 
animal-derived products such as serum or matrices in the process [38], the last of which 
can be crucial in the applicability of these derived cells to clinical applications. Most 
recently, it has been found that maintenance of constant low oxygen during derivation of 
hESC enables the establishment of pre-X inactivated cells, which are similar to mESC, 
and exposure to 20% oxygen or oxidative stress irreversibly causes X inactivation [94].  
 
1.5.2 Pluripotency 
Low oxygen affected the pluripotent phenotype of mESCs when they were cultured with 
LIF [33]. Normally, mESC colonies have smooth edges, but this morphological 
phenotype was lost with low oxygen exposure, instead causing the colonies to have 
fibroblast-like morphologies [95] or to form jagged edges [96], both signs of early 
differentiation despite the presence of LIF.  These morphological changes were also 
associated with reduced levels of alkaline phosphatase activity and pluripotency gene 
(Oct4, Nanog, and Sox2) expression [95, 96].  One study [95] proposed that HIF-1α 
protein, the concentration of which increases at low oxygen, mediated suppression of 
the LIF-STAT3 pathway as evidenced by a reduction in the expression of the LIF 
receptor under hypoxia. Interestingly despite these observations, the cells maintained 
some potential to differentiate into cells of all three germ layers [96]. 
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In contrast to mESCs, expression of Oct4, Nanog, and Sox2 in hESCs were apparently 
not affected by hypoxic culture (2% to 5% oxygen) [94, 97, 98].  In one study, however, 
Nanog and Notch1 mRNA expression increased in hESCs cultured over a four-week 
period at 5% oxygen compared to those cultured under 20% oxygen. This difference 
was not maintained after long term culture under the hypoxic condition, since there was 
no significant difference in Nanog and Notch1 mRNA levels between cells cultured for 
18 months under either 5% or 20% oxygen. Consistent with earlier results, no 
differences in Oct4 expression were observed under both oxygen conditions with either 
short or long term culture [99]. However, a recent report showed down-regulation of 
Oct4, Nanog and Sox2 in HIF-2α silenced hESC, together with reduced proliferation 
[100]. 
 
Hypoxic culture resulted in wide-spread transcriptome differences in hESCs when 
compared to culture under ambient oxygen conditions, including downstream targets of 
the core pluripotency network Oct4, Nanog, Sox2. Genes marking early differentiation to 
all cell lineages were upregulated at 20% oxygen [94, 98]. In addition, Lefty2, a member 
of the TGFβ family of proteins, which is hypothesized to play a role in preventing 
differentiation, was down-regulated at 20% oxygen compared to culture at 4% [98]. This 
may lead to a greater proclivity for the hESC to differentiate. In studies on the 
transcriptome-wide effects of hypoxic culture on hESCs kept under self-renewing 
conditions, culture at 20% O2 resulted in greater heterogeneity amongst different hESC 
lines than when cultured under hypoxic (2-4% oxygen) conditions [101]. This 
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heterogeneity may arise from subpopulations of cells already undergoing early 
differentiation when cultured at 20% oxygen.  
 
While low oxygen appears not to affect pluripotency gene expression directly, 
differentiated areas of each colony expressing SSEA-1, a marker of early differentiation 
for hESCs, were reduced when cultured under 3% and 1% oxygen compared to culture 
under 20% oxygen [102]. In a different study, however, culture at 2% oxygen did not 
affect expression of either SSEA-4 or SSEA-1 in hESCs when compared to ambient 
oxygen conditions [97]. 
 
HIF-1α has been investigated as an important gene mediating ESC hypoxic response.  
One study [103] suggests a possible link connecting HIF-1α action with Notch signaling. 
In mouse embryonic teratocarcinoma cells and neural stem cells, hypoxia allowed for 
the accumulation of HIF-1α, which stabilized the Notch intracellular domain, in turn 
promoting the undifferentiated phenotype. The action of Notch in promoting self-renewal 
appears to be conserved in hESCs in view of a recent demonstration that self-renewal 
is mediated by activation of the Notch pathway and that benefits of hypoxic culture were 
eliminated with inhibition of Notch signaling [99]. Interestingly, although another 
hypoxia-inducible factor in the same family as HIF1α, HIF-2α has not been shown to be 
active in mESC [91], other studies have shown that it is the HIF-2α heterodimer and not 
HIF-1α that can induce transcription of Oct4 [104], providing a potential link between 
culture oxygen levels and pluripotency gene expression in ESC. Several studies 
suggested that the hypoxic response mediated by HIF-1α is transient and not sustained 
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with chronic hypoxia or normoxia [94, 99]. However, it is the HIF-2α response that may 
influence pluripotency gene expression after long-term continuous culture under hypoxic 
conditions [100]. 
 
1.5.3 Proliferation 
Many studies have found that low oxygen affects proliferation, but this effect varied 
between studies and cell lines.  In one study [93], proliferation of mESCs increased 
under 5% compared to 20% oxygen, while in another [96], no difference was observed 
in one cell line and a small increase in another. Culture at 1% oxygen or lower, however, 
reduced the rate of proliferation compared to 20% [95, 96]. mESCs were able to adapt 
and continue to proliferate under anoxia, albeit with a longer doubling time compared to 
20% oxygen, and had the ability to utilize anaerobic respiration exclusively for their 
energy requirements [96].  Similarly disparate results have been reported for hESCs:  In 
one study, proliferation rates at 5% oxygen were reduced compared to 20% [99], in 
another, no differences in the rates were observed at 5% and 3% and only a slight 
reduction at 1% [102].  A conflicting recent report showed that low oxygen culture 
increased proliferation of hESC [100]. 
 
1.5.4 Clonal recovery 
Low oxygen culture improved clonal recovery after passaging. mESCs passaged at 5% 
oxygen [34] and hESCs at 2% [101, 105] had improved clonal survival. Cytogenetic 
instability at high passages for mESCs was not reduced in culture at 5% oxygen [92], 
and further reductions in oxygen to even 0% did not affect the amount of oxidative DNA 
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damage incurred by the cells [96]. In contrast for hESCs, 2% oxygen reduced 
chromosomal abnormalities after multiple passages [101], suggesting a further benefit 
of hypoxic culture.  
 
1.5.5 Reprogramming 
Moderate hypoxic conditions improved reprogramming of somatic cells to iPSC for both 
mouse and human lines. Performing reprogramming at 5% oxygen increased the 
number of iPSC colonies generated over both 20% and 1% oxygen conditions [106]. It 
is possible that this increase in reprogramming efficiency may be due to increased 
proliferation under 5% oxygen, as reprogramming is a stochastic process that can be 
accelerated by increasing rates of cell division [107]. 
 
1.5.6 Control of pO2cell 
Most of the studies reviewed in this section implicitly make the assumption that the 
oxygen levels in the bulk gas phase (pO2gas) was equal to the actual levels of oxygen 
experienced by the cell (pO2cell).  However, pO2cell can differ drastically from 
pO2gas,depending on the cell density, medium height, cellular oxygen consumption rate, 
and oxygen permeability of the culture substrate [108]. Furthermore, step changes in 
pO2gas due to removal of culture dishes from the incubators may result in transient 
changes in pO2cell with long time scales for equilibration.  These problems are 
ameliorated by culturing the cells on the surface of a membrane with very high oxygen 
permeability, such as silicone rubber.    
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Differences in pO2cell between different experiments carried out at the same pO2gas 
provide a possible explanation for the inconsistencies in data reported.  For instance, 
one study [99] reported reduced proliferation of hESCs cultured at 5% oxygen, and 
another [102] reported no reduction in proliferation at the same oxygen condition.  In the 
first study, there were four weeks between passages (initial and final cell numbers not 
reported).  In the second study, 6x105 cells were plated per well of standard six-well 
tissue culture plates,  and there were only two weeks between passages, with final cell 
numbers of 1.5-2.5x106 cells per well. It is possible that the pO2cell of the first study was 
significantly lower than the pO2gas because of higher cell densities, in particular after 
extended culture without passage, while pO2cell in the latter study was closer to pO2gas.  
This would help explain the differences in results because the authors of the second 
study report a reduced proliferation at 1% gas phase oxygen level, which may be closer 
in cellular oxygen level to the 5% gas phase oxygen level of the first study that also 
demonstrated a reduced proliferation rate.  Moreover, the first group used the Xvivo 
system (BioSpherix, Lacona, NY), which allowed for continuous culture low pO2gas 
without interruption for media changes and passaging.  The second group used a 
conventional sealed chamber from which cells were periodically removed for media 
changes and passaging, allowing for periods where pO2gas is at ambient levels, 
disrupting the low pO2cell conditions. Without information regarding the experimental 
conditions, especially the media heights and cell densities, it is impossible to draw any 
conclusions. 
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The lack of recognition that pO2cell is often different from pO2gas, sometimes by a 
substantial amount, is exacerbated because values of cell density and media height 
necessary for retrospective estimation of pO2cell are often not reported.  Knowledge of 
pO2cell is necessary for interpreting the results of studies and comparing them to data 
from other studies. Efforts to estimate or control pO2cell are essential for rational 
advancement of this field. 
 
1.5.7 Effects on subsequent differentiation 
Given that low oxygen partial pressure (pO2) is an important physiological cue during 
development [109], it is not surprising that low pO2 during differentiation markedly 
influences resulting cell fates [110–116]. One example is the increase in fraction and 
number of cardiomyocytes by low oxygen culture during the first 6 days of differentiation 
[117]. However, despite the many studies on the effects of oxygen levels employed 
during self-renewal culture, its effect on subsequent differentiation of PSC is largely 
unknown. A naïve hypothesis based on the previous two observations may be that 
since low oxygen is beneficial to cardiomyogenesis in early differentiation, low oxygen 
culture during self-renewal immediately before differentiation would have a synergistic 
positive effect as well. Given the effects of oxygen levels on self-renewal culture, it is 
important to study the effects of modulating oxygen on subsequent differentiation, since 
it is the differentiated cells that are of therapeutic importance.  
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1.6 Use of 2i in PSC derivation and propagation 
Small molecules that are able to target specific signaling pathways or proteins have 
been invaluable in advancing stem cell culture. They allowed for defined conditions and 
media to be used in the generation, propagation, and differentiation of the desired cell 
types [118]. In particular, this thesis focuses on the use of a pair of small molecule 
inhibitors – PD0325901, a Mitogen-Activated Protein Kinase (MEK) inhibitor [119], and 
CHIR99021, a Glycogen Synthase Kinase 3β (GSK3β) inhibitor [120], together known 
as ‘2i’ [121].  
 
PD0325901 acts as a MEK1/2 inhibitor that prevents the phosphorylation of ERK1/2, a 
kinase that can activate transcriptional activity associated with activation of the RTK 
(Receptor Tyrosine Kinase) signal transduction pathway associated with the Fibroblast 
Growth Factor (FGF). CHIR99021 acts as a GSK3β inhibitor that mimics the activation 
of the canonical Wnt pathway. Activation of the Wnt pathway or application of 
CHIR99021 prevents the degradation of β-catenin and allows for its translocation to the 
nucleus, dimerization with LEF/TCF, and subsequent transcriptional activity [122]. 
 
2i was first identified as a replacement for LIF to allow for undifferentiated propagation 
of mESC [34]. It improves the efficiency of reprogramming of mouse iPSC to the naïve 
state when used together with LIF [121]. Along the same vein, 2i use in culture of 
mouse epiblast stem cells (mEpiSC), considered a “primed” state of pluripotency, can 
convert the cells to a “mESC-like” naïve state [123]. More recently, 2i, when used with 
ectopic gene expression, LIF, and Forskolin, is able to convert hESC to become a naïve 
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LIF-responsive state [124]. Furthermore, a cocktail of 2i with PD173074, a Fibroblast 
Growth Factor Receptor (FGFR) inhibitor, and Y27632, a Rho Kinase (ROCK) inhibitor, 
was able to maintain the undifferentiated state of hESC without feeder cells with single-
cell passaging [125]. 
 
The increasing use of highly specific small molecules in defined stem cell culture, in 
particular, in propagating undifferentiated cells, raises the question about their 
downstream effects on subsequent differentiation of the cells. Studies have shown 
effects on expression of core pluripotency genes including Oct4, which affect cell fate 
during differentiation. It is thus not inconceivable that small molecule use during self-
renewal would have effects on cell fate after subsequent differentiation. 
 
1.7 Objectives  
In order for PSC to fulfill their immense clinical and research potential, there must exist 
efficient methods for directing differentiation to the desired cell types. Two aspects that 
have been largely ignored have been differences within a clonal population that may 
exist due to cell-to-cell variation, and differences between clonal populations that have 
been subjected to different culture conditions that support undifferentiated PSC self-
renewal but may manifest differences in subsequent differentiation. The central 
hypothesis behind this thesis is that the starting “state” of a mESC affects the resulting 
cell fate after subsequent differentiation, despite using undifferentiated mESC from the 
same cell line that were also subjected to the same differentiation protocol. The 
objectives of this research were to identify effects of cell-to-cell variability and self-
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renewing culture conditions (including culture oxygen levels and the use of small 
molecule inhibitors) immediately before the initiation of differentiation on the efficiency of 
established directed differentiation protocols in order to further improve them. This 
research would establish a novel dimension to explore in the design of future directed 
differentiation protocols. 
 
1.8 Overview  
Chapter 2: Cell-to-cell variability within an undifferentiated clonal population affects 
subsequent differentiation of mouse embryonic stem cells 
 
This chapter describes the effects of differences within cells of an undifferentiated 
population of mESC, specifically Oct4 expression in single cells, on their efficiency of 
subsequent differentiation to cardiomyocytes. Using a mESC line harboring a GFP 
reporter driven by the Oct4 distal enhancer, subpopulations of mESC with high, medium, 
or low Oct4-GFP levels were sorted by FACS and assessed for pluripotency and early 
differentiation markers. Sorted cells were differentiated immediately or allowed to self-
renew before subsequent differentiation. (1) Differentiation immediately after sorting 
examined the effects of the initial levels of Oct4 expression on the differentiated cell fate; 
(2) self-renewal after sorting examined if the subpopulations are stably distinct or if the 
differences are transient; and (3) differentiation after the subpopulations have been 
allowed to self-renew examines if subpopulations with different differentiation 
efficiencies as found in (1) could be stably isolated and propagated. Differentiated cells 
were assessed for fractions of residual undifferentiated Oct4-GFP+ cells, 
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immunostained with MF20 antibodies for presence of sacromeric myosin heavy chain, 
and assessed for cardiac gene expression by qRT-PCR. 
 
Chapter 3: Culture oxygen levels and use of small molecule inhibitors during self-
renewal reversibly affect subsequent differentiation of mouse embryonic stem cells 
 
This chapter describes the effects of culture oxygen levels and use of a small molecule 
inhibitor cocktail (‘2i’) during self-renewal (termed ‘preconditioning’) on subsequent 
differentiation of mESC. mESC were kept in undifferentiated culture with strict control of 
cellular oxygen levels using silicone rubber membrane-based culture plates in 
conditions of 20%, 5%, or 1% oxygen, with or without addition of 2i in LIF supplemented 
medium. Cells self-renewed under different conditions were assessed for levels of Oct4-
GFP expression and gene expression of pluripotency and early lineage markers. Cells 
were subsequently differentiated and assessed for efficiency of differentiation to 
cardiomyocytes by immunostaining for sacromeric myosin heavy chain protein, qRT-
PCR assessment of cardiac gene expression, and semi-quantitative assessments of 
spontaneously contracting cells. In addition, the reversibility of different preconditioning 
effects was examined – for cells that received low oxygen preconditioning, further self-
renewal at 20% oxygen before differentiation; and for cells that received 2i 
supplementation during the initial 9 day preconditioning, further self-renewal without 2i 
supplementation before differentiation. In addition, the synergistic effects of combining 
preconditioning that produces the most efficient differentiation to cardiomyocytes with 
low oxygen during differentiation that has previously been shown to improve 
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differentiation were examined. Finally, a mathematical model describing the relationship 
between the fraction of cardiomyocytes in the differentiated populations with the initial 
mean Oct4-GFP levels was developed. 
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Chapter 2 Cell-to-cell variability within an undifferentiated clonal 
population affects subsequent differentiation of mouse embryonic 
stem cells 
 
2.1 Abstract 
Differentiation of embryonic stem cells (ESC) typically results in a mixture of cell types 
despite use of a clonal starting population of genetically identical undifferentiated cells 
and of efforts to control the culture microenvironment. One cause may be cell-to-cell 
variability in gene expression, which results in a distribution of mRNA and protein levels, 
including those of key transcription factors governing ESC pluripotency and 
differentiation. Here we investigate how different levels of Oct4 expression resulting 
from cell-to-cell variation in a clonal undifferentiated population of mouse ESC (mESC) 
affect their proclivities to differentiate into cardiomyocytes, chosen here as a model 
system. Using a mESC line harboring a GFP reporter driven by the distal Oct4 
enhancer, we found large cell-to-cell variability in Oct4-GFP expression in a clonal 
population of undifferentiated cells. These differences could not be attributed to cell 
cycle variation alone. Subpopulations with different levels of Oct4-GFP exhibited large 
differences in expression of pluripotency and early differentiation markers. 
Subpopulations sorted through FACS with higher starting Oct4-GFP levels differentiated 
into populations with greater fractions and numbers of cardiomyocytes. However, if the 
sorted populations were allowed to self-renew, they recapitulated the parental 
distribution of Oct4-GFP expression over a time period measured in days, and this 
erased the differences in expression of pluripotency and early differentiation markers 
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found immediately after sorting. Sorted populations that were allowed to recapitulate the 
parental Oct4-GFP distribution before subsequent differentiation did not exhibit 
differences in the resulting differentiated populations. These results indicate that cell-to-
cell variation within a clonal population during self-renewal prior to differentiation of 
mESC can affect the outcome of differentiation. 
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2.2 Introduction 
Pluripotent stem cells (PSC), including embryonic stem cells (ESC) and induced 
pluripotent stem cells (iPSC), with their ability to differentiate into all cell types of the 
adult organism, have enormous potential as a source of replacement tissue for 
regenerative medicine [4, 24], for studying disease development [22], and for drug 
screening [126]. One of the main obstacles to their successful application, however, is 
the need to produce sufficient quantities and purities of viable terminally differentiated or 
progenitor cells of the desired type [5].  
 
Differentiation of PSC in vitro typically results in a heterogeneous mixture of different 
cell types [49], despite a starting population of genetically-identical cells and efforts to 
control the culture microenvironment. Prior studies on directing differentiation of PSC 
have focused on the process of differentiation, with much effort going to optimizing 
cellular microenvironments during differentiation [127]. However, heterogeneity in the 
resulting differentiated cells may have been caused by cell-to-cell variability in the 
undifferentiated population, even before differentiation had been initiated. This cell-to-
cell variability manifests as a distribution of mRNA and protein levels, including those of 
key transcription factors governing ESC pluripotency and differentiation. 
 
Indeed, this has shown to be true in clonal hematopoietic stem cells which exhibit cell-
to-cell transcriptome-wide differences and also correspondingly different proclivities to 
differentiate into different cell lineages [72]. Studies with ESC have shown that there is 
heterogeneous expression of Nanog within a clonal undifferentiated population, and its 
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transient down-regulation allows for cells to differentiate [49], [50]. More recently, 
heterogeneous expression of Rex1 and Stella have also been shown in mESC, and 
mESC when kept in the undifferentiated state, can interconvert between Rex1+ and 
Rex1-, and Stella+ and Stella- states. More significantly, when these subpopulations are 
differentiated, Oct4+/Rex1- mESC showed increased efficiency in differentiation to 
somatic cells of mesodermal and ectodermal lineages, while Oct4+/Rex1+ mESC 
differentiated more efficiently to primitive endoderm [52]. Similarly, Oct4+/Stella-
/Pecam- mESC showed increased efficiency in neuronal and trophectodermal 
differentiation compared to Oct4+/Stella+/Pecam+ mESC [53]. 
 
Prior studies have noted the role of Oct4 in fate choice in differentiating ESC. Ectopic, 
quantitative increases or decreases in expression of Oct4 control lineage commitment 
[45, 46, 128]. In addition, the interplay of Oct4, Sox2 and Sox17 during early 
differentiation affects hESC differentiation to cardiomyocytes [129]. Finally, upon 
initiation of differentiation, Oct4 and Sox2 play significant roles in germ layer 
determination [48]. 
 
Here, we investigate how different levels of Oct4 expression resulting from cell-to-cell 
variation at the initiation of differentiation of a clonal mouse ESC (mESC) population 
affect their proclivities to differentiate into cardiomyocytes, chosen here as a model 
system. We use a transgenic mESC reporter line harboring a GFP sequence driven by 
the Oct4 distal enhancer, active in the naïve pluripotent state [130, 131], to allow for 
non-invasive measurements of Oct4 expression levels. We also study the behavior of 
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subpopulations within a clonal undifferentiated population with different measured levels 
of Oct4-GFP expression when these subpopulations were allowed to self-renew in order 
to determine if cell-to-cell variations in Oct4-GFP are fixed or transient and if they retain 
their differences in affecting subsequent differentiation.  
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2.3 Methods 
2.3.1 Self-renewing culture of mESC 
A transgenic R1 mESC reporter line harboring a GFP sequence driven by the Oct4 
distal promoter (O4G) [132], generously donated by Professor Douglas Melton (Harvard 
University, Cambridge, MA, USA), was used for the experiments. Undifferentiated O4G 
mESC were propagated as previously described [96] in Dulbecco’s modified Eagles 
medium optimized for ES cells (ES-DMEM; SCRR-2010; American Type Culture 
Collection (ATCC), Manassas, VA, USA) supplemented with 10% (v/v) ES cell qualified 
fetal bovine serum (FBS; SCRR 30-2020; ATCC), 2 mM L-alanyl-L-glutamine (SCRR 
30-2115; ATCC), 100 units/mL penicillin and 100 µg/mL streptomycin (30-002-CI; 
Mediatech, Manassas, VA, USA), 1x MEM non-essential amino acids (30-2116; ATCC), 
100 µM 2-mercaptoethanol (M7522; Sigma-Aldrich, St. Louis, MO, USA), and 103 
units/mL Leukemia Inhibitory Factor (ESGRO mLIF; ESG1106; Millipore, Billerica, MA, 
USA) on standard cell culture polystyrene plates (353043; BD Biosciences, Bedford, MA, 
USA) or flasks (353014; BD Biosciences) that have been previously treated for 30 min 
with a sterile 0.1% (w/v) solution of Type A gelatin (G-2500; Sigma-Aldrich) in tissue 
culture water (25-055-CM; Mediatech). Cells were plated at a density of 12,000 
cells/cm2. Medium was replaced daily, and cells were detached with 0.25% trypsin (30-
2101, ATCC) every 3 days and replated at 12,000 cells/cm2. 
 
2.3.2 Cell cycle analysis 
Undifferentiated O4G mESC were detached and incubated as a single cell suspension 
at a concentration of 106 cells/mL in undifferentiated culture media supplemented with 
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fumitremorgin C to a final concentration of 10 µM (F9054; Sigma-Aldrich) for 30 min 
before live cell staining of cellular DNA content was performed using Vybrant DyeCycle 
Violet Stain (V35003; Molecular Probes, Eugene, OR, USA) according to the 
manufacturer’s instructions. Samples were analyzed using a FACS LSR HTS-2 
(Beckton Dickinson) using 405 nm and 488 nm excitation sources (Koch Institute (KI), 
MIT, Cambridge, MA, USA). All flow cytometry data was analyzed using FlowJo (Tree 
Star, Ashland, OR, USA). Fluorescence was taken to be proportional to DNA content in 
individual cells, and the population distribution of DNA content was fitted to a Watson 
cell cycle model [133] in FlowJo, allowing for separation of the cell population into 
subpopulations of cells in G1, S, or G2 phases. 
 
2.3.3 Fluorescence-Activated Cell Sorting (FACS) of undifferentiated O4G cells 
Undifferentiated O4G mESC were sorted according to Oct4-GFP fluorescence in 
individual cells using a FACS Aria (Beckton Dickinson) or MoFlo (Beckman Coulter) into 
the highest 15% (‘High’), middle 15% (‘Mid’), and lowest 15% (‘Low’). As a control, cells 
were also passed through the sorter and all Oct4-GFP-positive cells were collected 
(‘All’).  R1 mESC without the reporter transgene were used as the negative gating 
control for Oct4-GFP expression.  
 
2.3.4 Flow cytometric analysis of Oct4-GFP expression 
Oct4-GFP fluorescence in individual cells was measured using a FACScan (Beckton 
Dickson). The fraction of Oct4-GFP positive cells was calculated as the number of cells 
above the negative gating threshold as defined above, divided by the number of cells in 
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the entire population at each specific measurement time and condition. For 
undifferentiated cells, the mean Oct4-GFP fluorescence was determined from all Oct4-
GFP positive cells in the population. 
 
2.3.5 Differentiation of mESC to cardiomyocytes 
Cells were differentiated as previously described [108]. Briefly, embryoid bodies (EBs) 
were formed with 500 mESC per drop in 20µL of cell culture medium as used in self-
renewing culture but without LIF and including 0.2 mM ascorbic acid (A4034; Sigma-
Aldrich). After 2 days, 30 EBs were transferred per well into fibronectin-coated (F1141; 
Sigma-Aldrich) silicone rubber membrane-based plates [108] filled with 2mL of the EB 
medium. After an additional 3 days, medium was replaced with 2.5mL of serum-free 
medium, consisting of 50% (v/v) DMEM (90-133-PB; Mediatech) in tissue culture water 
and 50% (v/v) Ham’s F-12 (10-080-CV; Mediatech) supplemented with 0.75% (w/v) 
sodium bicarbonate (25-035-CI; Mediatech), 9mM glucose (G8769;  Sigma-Aldrich), 5 
µg/mL human insulin (I9278; Sigma-Aldrich), 100 units/mL penicillin, 100 µg/mL 
streptomycin, and 0.2 mM ascorbic acid. Cells were differentiated at either 20% or 1% 
O2 throughout the entire protocol for 10 days with oxygen conditions maintained by 
flowing premixed gases containing 5% O2, and 20% or 1% O2 with a balance of N2 
(certified medical gas from Airgas, Hingham, MA, USA), which corresponded under 
humidified conditions to 142 and 7 mmHg pO2gas inside chambers maintained at 37oC  
[108].  
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2.3.6 Real-time polymerase chain reaction (PCR) 
Samples were collected as single cell suspensions and stored at 4oC in RNAprotect Cell 
Reagent (76526; Qiagen, Valencia, CA, USA) according to manufacturer’s instructions 
for no longer than 7 days before RNA isolation. Total RNA was isolated using the 
RNeasy Plus Mini Kit (74134; Qiagen), cDNA synthesized using the High Capacity 
cDNA Reverse Transcription Kit (4368814, Applied Biosystems, Foster City, CA, USA). 
Real-time PCR was performed on a Fast Real-Time PCR System (7900HT, Applied 
Biosystems), at the Center for Biomedical Engineering (MIT) using Power SYBR Green 
PCR Master Mix (4367659, Applied Biosystems) or Taqman Gene Expression Master 
Mix (43669016, Applied Biosystems) as appropriate. 18S ribosomal RNA (rRNA) was 
used as an endogenous control. Primer sequences used for Nanog, Oct4, Sox2, and 
Sox17 have been previously reported [96]. Additional primer sequences used (in order 
of forward and reverse primer, and 5’ to 3’) were cardiac α-Actin 
GCTTCCGCTGTCCAGAGACT and TGCCAGCAGATTCCATACCA, cardiac Troponin T 
(cTnT) AGATGCTGAAGAAGGTCCAGTAGAG and CACCAAGTTGGGCATGAAGA, 
Cdx2 TCACCATCAGGAGGAAAAGTGA and GCTCTGCGGTTCTGAAACCA, and GFP 
CTGCTGCCCGACAACCA and TGTGATCGCGCTTCTCGTT. Commercially available 
primers for 18S rRNA (Hs99999901_s1, Applied Biosystems) and Nestin 
(Mm03053244_s1, Applied Biosystems) were also used. A standard curve was 
constructed with cDNA pooled from all time points and conditions then serially diluted.   
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2.3.7 Cell enumeration 
Enumeration of viable cells in undifferentiated culture was performed by staining with 
Guava Viacount (4000-0041; Millipore) and data acquired using a Guava PCA flow 
cytometer (Millipore) according to manufacturer’s instructions. For differentiated cells, 
nuclei enumeration was performed by exposing dispersed cells to a lysis solution of 1% 
(v/v) Triton X-100 and 0.1 M citric acid (0627; Mallinckrodt Specialty Chemicals, Paris, 
KY, USA), then vortexed to obtain nuclei samples. Samples were then stained with 
Guava Viacount and data acquired [96].  
 
2.3.8 Flow cytometric analysis of MF20+ cells 
The fraction of MF20+ cells in dispersed cells was acquired with flow cytometry as 
previously described [96]. Briefly, samples were fixed by a 20 min incubation in 1% (w/v) 
paraformaldehyde (36606; Alfa Aesar, Ward Hill, MA, USA) in PBS. Fixed cells were 
permeabilized in 0.5% saponin (S-4521; Sigma-Aldrich) for 10 min, non-specific binding 
blocked by a 30 min incubation in 2% (v/v) FBS in PBS, and then incubated at room 
temperature with primary antibodies against sarcomeric myosin heavy chain (MF20; 
MF20 supernatant; Developmental Studies Hybridoma Bank, Iowa City, IA, USA) diluted 
1:10 in 2% FBS solution for 1 hr. Samples were then incubated with goat anti-mouse 
phycoerythin-conjugated secondary antibodies (115-116-146; Jackson 
ImmunoResearch; West Grove, PA, USA) diluted 1:250 in 2% FBS solution for 30 min 
at room temperature in the dark, washed 3x in 2% FBS solution, then data acquired 
using a FACScan.  
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2.3.9 Statistics 
Statistical analysis was performed with unpaired two-tailed t-tests, with p<0.05 
considered statistically significant. Error bars are ± 1 standard deviation calculated from 
biological replicates. 
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2.4 Results 
2.4.1 Large cell-to-cell variability in Oct4-GFP expression in undifferentiated 
mESC which corresponds to Oct4 mRNA expression 
Flow cytometric analysis of Oct4-GFP fluorescence in a clonal population of 
undifferentiated O4G mESC revealed a large range of Oct4-GFP fluorescence 
intensities in individual cells, much larger the broadening attributable to instrument 
errors or resolution limitations as shown by measurements with reference fluorescence 
beads (SPHERO Rainbow Calibration Particles; RCP-30-5; Spherotech, Lake Forest, IL) 
(Figure 2-1A). Using FACS, cells were sorted into high, med, and low subpopulations 
(Figure 2-1B). Oct4-GFP fluorescence intensity, and Oct4 and GFP mRNA levels of the 
subpopulations correlated positively (Figure 2-1C & D). A clonal population of O4G 
mESC expressed cell-to-cell variation in Oct4-GFP fluorescence intensities that 
spanned over two orders of magnitude, which was reflected by the 60x difference in 
Oct4 mRNA levels between the high and low subpopulations.  
 
2.4.2 Distribution of Oct4-GFP is not entirely cell cycle dependent 
We next tested the hypothesis that this variation is cell cycle dependent by analysis of 
DNA content and corresponding Oct4-GFP fluorescence intensity in individual cells 
(Figure 2-2). Fractions of cells in G1, S, and G2/M phases were similar to other 
published data for mESC [134]. The Oct4-GFP fluorescence profiles for cells in each 
cell cycle phase exhibited the same large range of intensities as the whole population 
with large overlap amongst all three phases. Although peak intensity for cells in G2 was 
1.2x higher than cells in S phase, and both the aforementioned were higher than cells in 
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G1 (G2 by 1.5x, S by 1.2x), the differences in peak intensities were much smaller than 
the range of fluorescence intensities for cells in all three phases, which spanned more 
than 2 orders of magnitude. These differences between the subpopulations in different 
phases of the cell cycle were not significant at the 95% confidence interval. 
 
2.4.3 Levels of Oct4-GFP mark undifferentiated subpopulations with different 
levels of pluripotency and early differentiation markers 
mRNA expression analysis by real-time PCR revealed cell-to-cell variability in 
expression of pluripotency and early lineage markers within the clonal undifferentiated 
population. The sorted subpopulations showed that expression of pluripotency 
associated genes Oct4, Nanog, and Sox2 [39–41] correlated positively with each other, 
with each gene showing a greater than an order of magnitude difference in expression 
between the high and low subpopulations (Figure 2-3A-C). Trophectodermal marker 
Cdx2 [135], early endodermal marker Sox17 [136] and neural stem cell marker Nestin 
[137] showed the reverse trend, with higher expression in the Low subpopulation. 
Expression of Cdx2 was 200x higher, Sox17 20x higher, and Nestin 10x higher in the 
Low subpopulation than in the High subpopulation (Figure 2-3D-F), despite all cells 
being Oct4-GFP+.  
 
2.4.4 Populations differentiated from cells with higher initial Oct4-GFP levels had 
a greater fraction and number of cardiomyocytes 
Prior studies have shown that ectopically increasing levels of Oct4 in ESC cause 
spontaneous differentiation into the mesodermal lineage [45] and that Oct4 plays a role 
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in fate specification during early differentiation [48], [129]. We hypothesized that natural 
cell-to-cell variations in clonal mESC can affect the proclivity of individual cells in the 
population to differentiate into cells of different lineages, specifically that cells with 
higher Oct4-GFP at the initiation of differentiation would differentiate into 
cardiomyocytes with greater efficiency. To test this, we sorted the cells as described 
above and immediately initiated differentiation by EB formation. In addition, as a control, 
a 4th population of cells that had simply been passed through the FACS instrument and 
all Oct4-GFP+ cells collected (‘All’) was differentiated in the same manner as well to 
control for the effects of FACS. Each subpopulation was differentiated separately at 20% 
and 1% O2 throughout the entire differentiation protocol (Figure 2-4). 
 
Despite the clonal nature of the starting cells, the subpopulations differentiated into cells 
positively stained for MF20 (anti-sacromeric myosin heavy chain, a cardiac specific 
antibody [112], [138], [139]) with different efficiencies. Cells differentiated at 20% O2 
from the high subpopulation were 8.6% MF20+ compared to 4.2% from the low 
subpopulation, and when differentiated at 1% O2, the high subpopulation produced 21.7% 
MF20+ compared to 14.1% MF20+ from the low subpopulation (Figure 2-4A). Following 
the trend, the med and all subpopulations both produced fractions in between the high 
and low subpopulations in both cases. These results also replicated earlier studies that 
low oxygen during differentiation increased cardiomyocyte formation [117], [140].  
 
The positive correlation between initial Oct4-GFP fluorescence and differentiated 
MF20+ fractions was retained within each oxygen level by the total number of MF20+ 
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cells produced (Figure 2-4B), which was calculated by multiplying the fraction of MF20+ 
cells by the total number of cells in each differentiated subpopulation (Figure 2-4C). 
There were no statistically significant differences in the total cell numbers in the 
populations that were differentiated at the same O2, although differentiation at 1% O2 
produced less than 50% of the total cell number than differentiation at 20% O2. In 
addition, the fraction of residual Oct4-GFP+ cells (Figure 2-4D) and average 
fluorescence of these cells (data not shown) in each subpopulation were also only 
dependent on the differentiation O2 (with low O2 decreasing residual fraction of 
undifferentiated cells as previously shown [139, 140]). Finally, the trend of increasing 
MF20+ cells with increasing initial Oct4-GFP fluorescence were also corroborated by 
real-time PCR analysis (Figure 2-4E&F) of expression of cardiac genes Cardiac α-Actin 
[142] and cTnT [143].  
 
2.4.5 Sorted subpopulations recapitulate the parental Oct4-GFP distribution when 
allowed to propagate in self-renewing culture 
To investigate the stability of the cell-to-cell variation in Oct4-GFP expression intensities, 
we cultured the sorted subpopulations in self-renewing conditions and measured Oct4-
GFP fluorescence for up to 30 days (Figure 2-5 & 6). Within 12 hr of sorting, the cells 
repopulated the entire range of fluorescence intensities of the parental population, and 
the high and med subpopulations had similar peak intensities 3 days after the sorting. 
However, the low subpopulation took much longer to reconstitute the parental 
distributions, and still exhibited small differences (not statistically significant) up to 30 
50 
 
days after sorting with a broader distribution and proportionally more cells at lower 
intensities. 
 
2.4.6 Recapitulation of the parental Oct4-GFP distribution erases subpopulation 
differences in pluripotency and early differentiation markers 
We then hypothesized that the regeneration of parental Oct4-GFP levels would also 
remove differences in pluripotency and early differentiation markers observed in the 
subpopulation immediately after sorting. RNA was isolated from cells allowed to self-
renew for 30 days after sorting and levels of pluripotency and early differentiation genes 
were analyzed with real time PCR (Figure 2-7). The large differences in expression of 
all genes observed immediately after sorting (Figure 2-3) no longer existed in the 
subpopulations. 
 
2.4.7 Recapitulation of the parental Oct4-GFP distribution removes the 
differences in subsequent differentiation to cardiomyocytes 
Finally, we tested the efficiency of differentiation to cardiomyocytes of the regenerated 
subpopulations by differentiation at 1% O2 (Figure 2-8) There were no significant 
differences in the differentiated cells of the subpopulations in terms of fraction and 
number of MF20+ cells, and in the expression of Cardiac α-Actin and cTnT. 
 
In addition, the fraction of MF20+ cells (averaging 23.7%) differentiated from cells that 
had undergone the 30d regeneration after sorting (Figure 2-8A) was higher than those 
differentiated immediately after FACS (Figure 2-4A). The fraction of MF20+ cells was 
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higher than in the cells differentiated from cells simply passed through FACS without 
sorting (all population) (14.1%) and comparable to the high subpopulation (21.7%). We 
postulate that this difference could be due to the harsh treatment of cells during FACS 
and the extended period that the cells were kept outside the incubators at the initiation 
of differentiation. 
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2.5 Discussion 
Using an Oct4-GFP reporter driven by the distal enhancer active when mESC are in the 
naïve pluripotent state, we studied Oct4 expression in single cells of clonal populations 
of mESC, and observed large cell-to-cell variations in Oct4 within the undifferentiated 
populations. Levels of Oct4-GFP expression correlated positively with pluripotency gene 
expression and negatively with early differentiation markers. These differences 
translated into a greater fraction and number of cardiomyocytes after differentiation from 
cells with higher Oct4 expression at the initiation of differentiation. The cell-to-cell 
variation in Oct4 was transient, and sorted subpopulations with different levels of Oct4-
GFP expression reconstituted the parental distributions when allowed to self-renew over 
a period of 30 days. Allowing reconstitution of the parental distributions of Oct4-GFP 
also erased differences in pluripotency and early differentiation marker expression and 
in efficiency of subsequent cardiomyocyte differentiation. 
 
The differences in differentiation efficiencies of the sorted subpopulations were not due 
to greater cell survival or proliferation of select subpopulations because the total cell 
numbers after the differentiation were not significantly different. It also cannot be 
attributed to a resistance to or slower differentiation by the low subpopulation because 
the fraction of undifferentiated cells were the same in all populations differentiated at the 
same O2. Prior studies have shown that levels of Oct4 during early differentiation can 
influence the differentiation pathway of both human and mouse ESC, on some 
occasions by ectopically increasing or decreasing expression levels [45, 128, 129]. This 
study has shown that differences in Oct4 within undifferentiated clonal populations do 
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occur without intervention and, significantly, affect differentiation proclivities in the same 
manner.   It may seem that the results of this study contradict those of an early work 
which showed the heavy dependence of the pluripotent state of mESC on strict control 
over Oct4 expression [45], whereas this study has shown large variation in Oct4 
expression in mESC. An explanation could be the coordinated expression of Sox2 with 
Oct4 [144] in this study, rather than an ectopic change in Oct4 expression alone, that 
allows the mESC to retain the pluripotent state, thereby suggesting that future 
experiments of such a nature would benefit from studies of multiple genes 
simultaneously, as it may be their relative expressions that are significant.  
 
The observed cell-to-cell variation in Oct4 expression cannot be attributed entirely to the 
normal passage of cells through the cell cycle due to two observations – the small 
differences in Oct4-GFP of cells in different phases of the cell cycle, and the long time 
scale (up to 30 days or 60 cell divisions) required for the regeneration of the parental 
Oct4-GFP expression after FACS. We also note the significantly longer time required for 
the low subpopulation to recapitulate the parental distribution, and postulate that 
transitions to and from a low Oct4 state is slow. 
 
There have been many recent studies on sources of heterogeneities within clonal 
populations (reviewed in [80]). While studies have shown the mechanisms behind gene 
expression noise and their relationship to phenotypic differences [68, 78, 79, 144], the 
time scale for relaxation observed in this study suggests another source for the 
heterogeneity, in addition to noise. These slow fluctuations (such as the >18 day period 
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for regeneration of the sorted low population in this study) in mammalian cells remain 
poorly understood. It has been proposed that this heterogeneity in gene expression is 
based in epigenetics, influenced by (yet unidentified) non-stochastic factors; and most 
importantly, appears to have a role in development [80]. 
 
Prior studies of hematopoietic stem cells have shown transcriptome-wide differences in 
subpopulations sorted by expression of a surface antigen [72] which correlated to 
differentiation efficiencies to different cell lineages. Earlier studies have shown 
heterogeneous expression of Nanog [50], Rex1 [52], and Stella [53] in mESC which 
corresponded to effects on subsequent fate choice. This study has demonstrated a 
similar phenomenon based on levels of Oct4 gene expression in undifferentiated mESC, 
which may be correlated with the heterogeneous behaviors of the aforementioned 
genes. 
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2.6 Future Work 
Future studies could focus on further characterization of the sorted subpopulations of 
mESC, which could illuminate processes and mechanisms of early cell fate decisions 
during which different levels of pluripotency factors affect induction of different germ 
layers as demonstrated by a recent publication [48]. We hypothesize that the different 
starting levels of pluripotency factors at the initiation of differentiation ‘carry over’ into 
early differentiation, hence causing heterogeneity in germ layer induction. Other 
possibilities include the study of differentiation to other cell types of different lineages, 
such as neurons; improving the resolution of the sorted subpopulation by decreasing 
the range of Oct4-GFP intensities within each subpopulation, perhaps even down to the 
single cell level; simultaneous evaluation of multiple markers [146] to measure the ratios 
of two markers, such as Oct4 and Sox2 as suggested previously; elimination of cell 
cycle differences in the undifferentiated populations, perhaps by reversibly trapping the 
cells in one phase before sorting and differentiation [134]; and non-transgenic methods 
for non-destructive single cell measurements, perhaps by identifying the appropriate 
surface antigens suitable for translation to human pluripotent stem cell studies (e.g. 
SSEA4). Much about the dynamics of genome-wide interactions in such complex 
systems on the single cell level for both the maintenance of pluripotency and during 
differentiation remains to be studied. These studies could lead to a better understanding 
of the sources of heterogeneity within populations differentiated in vitro and improve 
yields of desired cell products from directed differentiation protocols.     
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2.7 Tables and Figures 
 
Figure 2-1 Characterization of Oct4-GFP (O4G) mESC reporter line demonstrates large 
cell-to-cell variability in Oct4-GFP expression which corresponds to Oct4 mRNA levels 
(A) Comparison of distribution of Oct4-GFP fluorescence and reference fluorescence 
beads. (B) Undifferentiated O4G mESC sorted by FACS into High, Med, and Low 
subpopulations. (C) Correlation between Oct4 mRNA expression (real-time PCR) and 
mean Oct4-GFP fluorescence (flow cytometry) [High = 1]. (D) Correlation between Oct4 
and GFP mRNA expressions (real-time PCR) [High = 1]. 
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Figure 2-2 Oct4-GFP variability cannot be explained by differences in cell cycle stage 
(A) Cell cycle analysis of undifferentiated and unsorted O4G mESC by fitting to a 
Watson cell cycle model [133] to identify cells in different cell cycle phases. (B) Oct4-
GFP distribution of undifferentiated O4G mESC at G1, S, and G2 phases of the cell 
cycle. 
 
DNA Content (DyeCycle Violet) [AU]
100
C
el
l C
ou
nt G1
S
G2
500
1200
900
600
300
0
Watson 
Model
A
Oct4-GFP Fluorescence [AU]
104
C
el
l C
ou
nt
s
G1
S
G2
103102
100
80
60
40
20
0
B
58 
 
 
 
 
Figure 2-3 Real-time PCR analysis of sorted O4G mESC subpopulations reveal that 
levels of Oct4-GFP mark undifferentiated subpopulations with different levels of 
pluripotency and early differentiation markers 
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Cells were sorted as described in Figure 2-1B into High, Med, or Low subpopulations. 
Relative expression of pluripotency-associated genes (A) Oct4, (B) Nanog, and (C) 
Sox2, and trophectodermal marker (D) Cdx2, and early differentiation markers (E) 
Sox17 and (F) Nestin [High = 1] (N = 3). 
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Figure 2-4 Populations differentiated from cells with higher initial Oct4-GFP levels had a 
greater fraction and number of cardimyocytes  
Cells were sorted as described in Figure 2-1B into High, Med, or Low subpopulations, or 
simply passed through FACS without selection (All subpopulation) as a control, and 
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immediately differentiated using the cardiomyocyte protocol at 20% or 1% O2 for 10 
days, then analyzed. 
(A) Fraction of MF20+ cells. (B) Final number of MF20+ cells. (C) Total cell count. (D) 
Fraction of residual Oct4-GFP+ cells. Real-time PCR analysis of cardiac markers (E) 
cardiac α-Actin, and (F) cTnT relative to undifferentiated mESC.(Error bars = standard 
deviation; N = 3; * indicates statistical differences at 95% confidence.) 
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Figure 2-5 Oct4-GFP fluorescence distributions of sorted subpopulations cultured in 
self-renewing conditions for up to 30 days after initial sorting demonstrate recapitulation 
of the parental Oct4-GFP distribution over time. 
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Figure 2-6 Time course of mean Oct4-GFP fluorescence of the subpopulations relative 
to the All subpopulation. 
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Figure 2-7 Effects of regeneration of parental Oct4-GFP expression on gene 
expression of subpopulations. 
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Cells sorted as described in Figure 2-1B were grown in self-renewing conditions for 30 
days before real-time PCR analysis of gene expression.  
Relative expression of pluripotency-associated genes (A) Oct4, (B) Nanog, and (C) 
Sox2, and trophectodermal marker (D) Cdx2, and early differentiation markers (E) 
Sox17 and (F) Nestin [High = 1]. (Error bars = standard deviation; N = 3; No statistically 
significant differences between gene expression of the regenerated subpopulations 
were found). 
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Figure 2-8 Recapitulation of the parental Oct4-GFP distribution removes the differences 
in subsequent differentiation to cardiomyocytes  
Cells were sorted and allowed to grow in self-renewing conditions for 30 days as 
described in Figure 2-7 were then subjected to cardiomyocyte differentiation for 10 days 
at 1% O2, then analyzed. 
(A) Fraction and (B) Number of MF20+ cells in the final differentiated populations. Real-
time PCR analysis of cardiac markers (C) cardiac α-Actin and (D) cTnT in the 
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differentiated populations relative to undifferentiated mESC. (Error bars = standard 
deviation; N = 3) 
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Chapter 3 Culture oxygen levels and use of small molecule inhibitors 
during self-renewal reversibly affect subsequent differentiation of 
mouse embryonic stem cells 
 
3.1 Abstract 
Prior studies on self-renewal culture of embryonic stem cells (ESC) which had focused 
on long term proliferation and pluripotency, with assessment by differentiation to 
derivatives of the three germ layers, include the discovery of different states of 
pluripotency, some achieved by small molecule inhibition of signaling pathways. The 
effects of culture conditions during self-renewal, (which we term preconditioning), on the 
effectiveness of subsequent differentiation has not been examined. Here we show that 
changes preconditioning by low oxygen culture or small molecule dual inhibition (2i) of 
mitogen-activated protein kinase (using MEK inhibitor PD0325901) and glycogen 
synthase kinase (with GSK inhibitor CHIR99021) (1) reversibly affect levels of Oct4 
expression in cells that are otherwise pluripotent, and (2) alters the efficiency of 
subsequent differentiation to cardiomyocytes (CM). Using a mESC line harboring a GFP 
reporter driven by the distal Oct4 enhancer, we performed preconditioning at different 
oxygen levels, with or without 2i supplementation. Under all conditions, the fraction of 
Oct4-GFP+ cells remained relatively constant (>90%) but the mean Oct4-GFP 
expression increased with 2i supplementation and decreased with low oxygen culture. 
Changes in preconditioning cells produced large differences in the resulting number and 
fraction of CM, despite use of identical differentiation protocols. Preconditioned cells 
that expressed higher Oct4-GFP levels before differentiation produced more CM after 
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differentiation. Low oxygen culture reduced Oct4-GFP expression during self-renewal 
and subsequent efficiency of CM differentiation while 2i supplementation increased both 
Oct4-GFP expression and subsequent efficiency of CM differentiation. These changes 
were reversed by continued self-renewal at high oxygen or removal of 2i 
supplementation respectively. Finally, the enhancement in CM generation from high 
oxygen culture and 2i supplementation during preconditioning is synergistic with low 
oxygen culture during differentiation, which had earlier been shown to improve 
differentiation of mESC to cardiomyocytes, demonstrating the importance of strict 
oxygen control during all aspects of ESC culture and differentiation. These results 
demonstrate that the manipulation of self-renewing culture conditions can lead to 
changes in the outcomes of defined differentiation protocols, a novel dimension to 
explore for directed differentiation of pluripotent stem cells.  
  
71 
 
3.2 Introduction 
In order to realize the immense clinical potential of pluripotent stem cells (PSC), which 
include both embryonic stem cells and induced pluripotent stem cells (iPSC), efficient 
protocols to differentiate these PSC into sufficient numbers and purities of the desired 
terminally differentiated or progenitor cell types are required. Much work in this area of 
directed differentiation has focused on the period during which differentiation is already 
occurring, and this includes differentiating ESC by co-culture with stromal cell lines [62], 
differentiation with various small molecule growth factors [60], and genetic 
manipulations [147]. However, the effects of the self-renewal culture environment used 
to propagate the undifferentiated cells before the initiation of differentiation on the 
effectiveness of subsequent differentiation protocols have not been examined. 
  
Most prior studies on self-renewal culture of embryonic stem cells (ESC) focused on 
long term proliferation and pluripotency and were assessed by differentiation to 
derivatives of the three germ layers. One recent study highlighted the importance of 
pluripotency factors Oct4 and Sox2 in germ layer determination during early 
differentiation [48]. Another study revealed that low oxygen levels during self-renewing 
culture decreased population-averaged levels of Oct4 mRNA expression, although cells 
remained pluripotent [96]. Taken together, this would suggest that different culture 
conditions can affect key pluripotency marker expression while still maintaining 
pluripotency, and these differences may affect the subsequent differentiation of the cells. 
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We are thus interested in examining different pluripotency maintaining culture conditions 
that result in changes in pluripotency marker expression. Two variables of interest are 
(1) culture oxygen levels, and (2) the use of two small molecule inhibitors (known 
together as ‘2i’) which have been shown to able to replace leukemia inhibitory factor 
(LIF) in self-renewing culture of mESC [34]. Would changes in oxygen levels or 2i use 
during self-renewal affect subsequent differentiation of mESC? In addition, would such 
changes affect cells permanently or were they reversible? 
 
In this study, we examined the self-renewing culture conditions for mouse ESC that 
affect the expression of Oct4, a key pluripotency marker, using a transgenic mESC 
reporter cell line harboring a GFP sequence driven by the Oct4 distal enhancer. In 
addition, we studied how different culture conditions during self-renewal immediately 
before differentiation, which we termed ‘preconditioning’, affect the efficiency of 
differentiation to cardiomyocytes, chosen here as a model system. Finally, we examined 
if changes in Oct4 expression due to different self-renewing conditions continued to be 
plastic when self-renewal conditions were changed. This work explored a novel 
dimension that had been previously ignored in designing directed differentiation 
protocols, resulting in an enhanced differentiation protocol which could be used in 
conjunction with and enhance the efficiency of other existing differentiation protocols. 
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3.3 Methods 
3.3.1 Self-renewing culture of mESC 
A transgenic R1 mESC reporter line harboring a GFP sequence driven by the Oct4 
distal promoter (O4G) [132], generously donated by Professor Douglas Melton (Harvard 
University, Cambridge, MA, USA), was used for the experiments. Undifferentiated O4G 
mESC were propagated as previously described [96] in Dulbecco’s modified Eagles 
medium optimized for ES cells (ES-DMEM; SCRR-2010; American Type Culture 
Collection (ATCC), Manassas, VA, USA) supplemented with 10% (v/v) ES cell qualified 
fetal bovine serum (FBS; SCRR 30-2020; ATCC), 2 mM L-alanyl-L-glutamine (SCRR 
30-2115; ATCC), 100 units/mL penicillin and 100 µg/mL streptomycin (30-002-CI; 
Mediatech, Manassas, VA, USA), 1x MEM non-essential amino acids (30-2116; ATCC), 
100 µM 2-mercaptoethanol (M7522; Sigma-Aldrich, St. Louis, MO, USA), and 103 
units/mL Leukemia Inhibitory Factor (ESGRO mLIF; ESG1106; Millipore, Billerica, MA, 
USA) on plates with wells whose bottoms have been replaced by silicone rubber 
membranes [108] and previously treated for 30 min with a sterile 0.1% (w/v) solution of 
Type A gelatin (G-2500; Sigma-Aldrich) in tissue culture water (25-055-CM; Mediatech). 
In some cases, the medium was further supplemented with 1µM PD0325901 and 3 µM 
CHIR99021 (‘+2i’). Cells were plated at a density of 12,000 cells/cm2. Medium was 
replaced daily, and cells were detached with 0.25% trypsin (30-2101, ATCC) every 3 
days and replated at 12,000 cells/cm2.  
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3.3.2 Flow cytometric analysis of Oct4-GFP expression 
Oct4-GFP fluorescence in individual cells was measured using a FACScan (Beckton 
Dickson). The fraction of Oct4-GFP positive cells was calculated as the number of cells 
above the negative gating threshold as defined above, divided by the number of cells in 
the entire population at each specific measurement time and condition. For 
undifferentiated cells, the mean Oct4-GFP fluorescence was determined from all Oct4-
GFP positive cells in the population. 
 
3.3.3 Differentiation of mESC to cardiomyocytes 
Cells were differentiated as previously described [108]. Briefly, embryoid bodies (EBs) 
were formed with 500 mESC per drop in 20µL of cell culture medium as used in self-
renewing culture but without LIF and including 0.2 mM ascorbic acid (A4034; Sigma-
Aldrich). After 2 days, 30 EBs were transferred per well into fibronectin-coated (F1141; 
Sigma-Aldrich) silicone rubber membrane-based plates [108] filled with 2mL of the EB 
medium. After an additional 3 days, medium was replaced with 2.5mL of serum-free 
medium, consisting of 50% (v/v) DMEM (90-133-PB; Mediatech) in tissue culture water 
and 50% (v/v) Ham’s F-12 (10-080-CV; Mediatech) supplemented with 0.75% (w/v) 
sodium bicarbonate (25-035-CI; Mediatech), 9mM glucose (G8769;  Sigma-Aldrich), 5 
µg/mL human insulin (I9278; Sigma-Aldrich), 100 units/mL penicillin, 100 µg/mL 
streptomycin, and 0.2 mM ascorbic acid.  
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3.3.4 Control of culture oxygen levels (pO2cell) 
Cells were self-renewed and differentiated at combinations of 20%, 5%, or 1% O2 as 
specified, with oxygen conditions maintained by flowing premixed gases containing 5% 
O2, and 20%, 5%, or 1% O2 with a balance of N2 (certified medical gas from Airgas, 
Hingham, MA, USA), which corresponded under humidified conditions to 142, 36, and 7 
mmHg pO2gas inside chambers maintained at 37oC. Control of pO2cell equal to pO2gas 
was accorded by culture on custom-made silicone rubber membrane-based wells as 
previously described [108].  
 
3.3.5 Real-time polymerase chain reaction (PCR) 
Samples were collected as single cell suspensions and stored at 4oC in RNAprotect Cell 
Reagent (76526; Qiagen, Valencia, CA, USA) according to manufacturer’s instructions 
for no longer than 7 days before RNA isolation. Total RNA was isolated using the 
RNeasy Plus Mini Kit (74134; Qiagen), cDNA synthesized using the High Capacity 
cDNA Reverse Transcription Kit (4368814, Applied Biosystems, Foster City, CA, USA). 
Real-time PCR was performed on a Fast Real-Time PCR System (7900HT, Applied 
Biosystems), at the Center for Biomedical Engineering (MIT) using Power SYBR Green 
PCR Master Mix (4367659, Applied Biosystems) or Taqman Gene Expression Master 
Mix (43669016, Applied Biosystems) as appropriate. 18S ribosomal RNA (rRNA) was 
used as an endogenous control. Primer sequences used for Nanog and Sox17 have 
been previously reported [96]. Additional primer sequences used (in order of forward 
and reverse primer, and 5’ to 3’) were cardiac α-Actin GCTTCCGCTGTCCAGAGACT 
and TGCCAGCAGATTCCATACCA and cardiac Troponin T (cTnT) 
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AGATGCTGAAGAAGGTCCAGTAGAG and CACCAAGTTGGGCATGAAGA, and Cdx2 
TCACCATCAGGAGGAAAAGTGA and GCTCTGCGGTTCTGAAACCA. Commercially 
available primers for 18S rRNA (Hs03928990_g1, Applied Biosystems), Blimp1 
(Mm00476128_m1, Applied Biosystems), Dusp6 (Mm00518185_m1, Applied 
Biosystems), Fgf5 (Mm00438918_m1, Applied Biosystems), Rex1 (Mm03053975_g1, 
Applied Biosystems), Stella (Mm01184198_g1, Applied Biosystems), Titin 
(Mm00621005_m1, Applied Biosystems), and Wnt3a (Mm00437337, Applied 
Biosystems) were also used. A standard curve was constructed with cDNA pooled from 
all time points and conditions then serially diluted. 
 
3.3.6 Cell enumeration 
Enumeration of viable cells in undifferentiated culture was performed by staining with 
Guava Viacount (4000-0041; Millipore) and data acquired using a Guava PCA flow 
cytometer (Millipore) according to manufacturer’s instructions. For differentiated cells, 
nuclei enumeration was performed by exposing dispersed cells to a lysis solution of 1% 
(v/v) Triton X-100 and 0.1 M citric acid (0627; Mallinckrodt Specialty Chemicals, Paris, 
KY, USA), then vortexed to obtain nuclei samples. Samples were then stained with 
Guava Viacount and data acquired with a Guava PCA flow cytometer as previously 
described [96]. 
 
3.3.7 Flow cytometric analysis of MF20+ cells 
The fraction of MF20+ cells in dispersed cells was acquired with flow cytometry as 
previously described [96]. Briefly, samples were fixed by a 20 min incubation in 1% (w/v) 
77 
 
paraformaldehyde (36606; Alfa Aesar, Ward Hill, MA, USA) in PBS. Fixed cells were 
permeabilized in 0.5% saponin (S-4521; Sigma-Aldrich) for 10 min, non-specific binding 
blocked by a 30 min incubation in 2% (v/v) FBS in PBS, and then incubated at room 
temperature with primary antibodies against sarcomeric myosin heavy chain (MF20; 
MF20 supernatant; Developmental Studies Hybridoma Bank, Iowa City, IA, USA) diluted 
1:10 in 2% FBS solution for 1 hr. Samples were then incubated with goat anti-mouse 
phycoerythin-conjugated secondary antibodies (115-116-146; Jackson 
ImmunoResearch; West Grove, PA, USA) diluted 1:250 in 2% FBS solution for 30 min 
at room temperature in the dark, washed 3x in 2% FBS solution, then data acquired 
using a FACScan. 
 
3.3.8 Estimation of spontaneously contracting areas 
The fraction of well coverage by spontaneously contracting cells was averaged from 
measurements in 15 random 2 mm2 spots within each well by visual estimation as 
previously described [108]. 
 
3.3.9 Statistics 
Statistical analysis was performed with unpaired two-tailed t-tests, with p<0.05 
considered statistically significant. All data presented as mean ± standard deviation of 
biological replicates. 
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3.4 Results 
3.4.1 Self-renewal of mESC at low oxygen reduces expression of Oct4-GFP but 
does not increase rates of spontaneous differentiation 
To examine the effect of low oxygen on self-renewing culture of mESC, we cultured 
O4G mESC under 20%, 5%, and 1% O2 with self-renewal media on silicone rubber-
based plates for 9 days and measured their distributions of Oct4-GFP fluorescence at 
each cell passage (Figure 3-1). Culture at low O2 shifted the distribution of Oct4-GFP 
fluorescence towards reduced (but still Oct4-GFP+) values (Figure 3-2A and B) and 
reduced the population averaged value (Figure 3-2A). However, under all conditions the 
fraction of Oct4-GFP+ cells remained relatively constant and >90% (Figure 3-2B).  
 
A prior study reported a reduction in Oct4 mRNA expression in mESC cultured under 
low oxygen [96] but did not identify if it resulted from a reduction across individual cells 
in the population, or an increase in fraction of Oct4-negative cells. Our results indicate 
that there have not been increased differentiation (which would have resulted in an 
increase in the fraction of Oct4-GFP-negative cells) due to reduced oxygen culture, but 
rather, a reduction in the levels of Oct4-GFP in individual cells.  
 
3.4.2 Reduction of Oct4-GFP expression by low oxygen culture is reversed by 
continued self-renewal in 20% oxygen 
We next tested if the reduction in Oct4-GFP expression was reversible by subsequent 
self-renewal cultured at 20% O2 (Figure 3-1C and 3-2) Cells that were cultured at 5% or 
1% O2 for 9 days were cultured under self-renewing conditions for an additional 9 days 
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at either 20% O2 (indicated as 5 20 or 1 20) or the same low oxygen condition as 
the first 9 days. The additional 9-day self-renewing culture at 20% O2 reversed the 
reduction in Oct4-GFP expression caused by low O2 culture during the first 9 days and 
restored the Oct4-GFP distribution to that of cells that had been continuously cultured at 
20% O2 for all 18 days. Cells continuously cultured under low O2 conditions did not 
undergo reversal of the reduction.  
 
3.4.3 Low oxygen preconditioning decreases subsequent differentiation of mESC 
to cardiomyocytes 
We hypothesized that conditions of self-renewing culture immediately before 
differentiation (termed preconditioning) at different O2 would change the efficiency of 
differentiation of clonal mESC to different cell types. To test this, we preconditioned 
clonal mESC at 20%, 5% and 1% O2 for 9 days before differentiating each population of 
preconditioned cells at 20%, 5%, and 1% O2 for 10 days, for a total of 9 different 
combinations of preconditioning and differentiation conditions (Figure 3-3). 
 
At each differentiation condition, low oxygen preconditioning reduced the fraction and 
number of cells positively immunostained for MF20 (anti-sarcomeric myosin heavy 
chain, a cardiac specific antibody [112, 138, 139]). For cells differentiated at 5% O2, for 
example, about 15, 25, and 29% of the population were MF20+ in differentiated cells 
preconditioned at 1, 5, and 20% O2 respectively (Figure 3-3A). 
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These results are further supported by similar trends in cardiac gene expression 
(cardiac α-Actin [142], cTnT [143] and Titin [148]) by the differentiated populations, as 
well as semi-quantitative estimations of the fraction of spontaneously contracting tissue 
(Figure 3-3C to E).   
 
3.4.4 Total cell number and fraction of residual undifferentiated Oct4-GFP+ cells 
are not affected by preconditioning, but by oxygen conditions during 
differentiation 
To investigate the possibility that the reduction in cardiomyogenesis in low oxygen 
preconditioned cells was due to changes in cell proliferation or a ‘resistance’ to any 
differentiation, we examined the total cell number and the fraction of residual 
undifferentiated mESC (identified by Oct4-GFP fluorescence) in differentiated 
populations (Figure 3-4). Total cell number after differentiation did not exhibit significant 
differences among populations differentiated at the same O2, but showed differences 
between populations preconditioned at the same O2 and differentiated at different O2. 
For cells preconditioned at 20% O2, for example, (white bars in Figure 3-4A), cells 
differentiated at 20% produced 5.6x106, 4.1x106, and 2.2x106 total cells when 
differentiated at 20, 5, and 1% O2 respectively. 
 
While changes in preconditioning O2 produced differences in the fraction of residual 
Oct4-GFP+ cells for populations differentiated at 20% O2, such differences were not 
observed for those differentiated at 5% or 1% O2. Differences between populations 
preconditioned at the same O2 but differentiated at either 20% O2 or low (5% or 1%) O2 
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were significant in all cases. For example, cells preconditioned at 1% (black bars in 
Figure 3-4B) had about 7.5%, 0.8%, and 1.1% of the differentiated population remaining 
as Oct4-GFP+ when differentiated at 20, 5, and 1% O2 respectively. Similar behavior 
observed for cells preconditioned at 20% and 5% O2. 
 
3.4.5 Reduction in efficiency of cardiomyogenesis due to low oxygen 
preconditioning is reversible by self-renewal in 20% oxygen before differentiation 
To investigate if the change in differentiation efficiency of clonal mESC to 
cardiomyocytes by low oxygen preconditioning was reversible, we cultured cells under 
self-renewing conditions at either 20%, 5%, or 1% O2 for 18 days, or 5% or 1% for the 
first 9 days and then 20% for the next 9 days, before subjecting all five populations to 
cardiomyocyte differentiation at 5% O2 (Figure 3-5). 
 
We found that the changes produced by low oxygen preconditioning could be largely 
reversed by subsequent self-renewing culture at 20% O2 before differentiation. The 
fraction and number of MF20+ cells in the populations differentiated from either 20%, 
520%, or 120% preconditioned cells were not significantly different, and this trend is 
also seen in cardiac α-Actin gene expression analysis and estimations of spontaneously 
contracting areas. The cells that were preconditioned at 5% and 1% O2 for all 18 days, 
however, continued to exhibit the reduced differentiation efficiencies to cardiomyocytes. 
 
82 
 
3.4.6 2i use during self-renewal increases expression of naïve pluripotency 
markers, decreases early differentiation markers synergistically with high oxygen, 
and is reversible by subsequent self-renewing culture without 2i 
The fraction of MF20+ cells in the differentiated populations correlated positively with 
the mean Oct4-GFP fluorescence of the starting populations (Figure 3-6). This 
correlation suggested that preconditioning mESC to increase their Oct4-GFP levels 
before differentiation would increase the yield in subsequent differentiation to 
cardiomyocytes. Prior work [96] had shown that increasing O2 levels in self-renewing 
culture above 20% did not further increase pluripotency gene expression but instead 
decreased them, possibly due to increased cell death due to increased reactive oxygen 
species (ROS). We then explored an alternative strategy of using small molecule 
inhibitors known to support the undifferentiated state and identified the combination of 
two small molecules: PD0325901, an inhibitor of Mitogen-Activated Protein Kinase 
(MEK), and CHIR99021, an inhibitor of Glycogen Synthase Kinase (GSK), referred 
together as ‘2i’, as a possibility. 2i has been used previously to maintain the 
undifferentiated state of mESC without LIF, and to improve the establishment of ESC 
and iPSC lines. Its use is thought to promote entry into the naïve or ground state of 
pluripotency [34, 149]. However, their effects during self-renewing culture on ESC’s 
subsequent differentiation have not been studied. We hypothesize that 2i 
supplementation in self-renewal media would increase Oct4 expression in 
undifferentiated mESC and consequently increase the efficiency of subsequent 
differentiation to cardiomyocytes. 
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To study the effects of 2i in self-renewing culture of mESC, we cultured O4G mESC 
under four different self-renewing conditions – 20% O2, with (20/2iL) or without 2i (20/L), 
or 1% O2 with (1/2iL) or without 2i (1/L) for 9 days (See Figure 3-7 for nomenclature for 
the different conditions). 2i supplementation increased the Oct4-GFP expression without 
significant changes in the fraction of Oct4-GFP+ cells compared to self-renewal without 
2i supplementation at either O2. 2i supplementation acted synergistically with high 
oxygen during self-renewal to increase Oct4-GFP expression beyond levels of cells 
cultured at 1% O2 with 2i. After 9 days of culture, 20% O2 with 2i supplementation 
produced cells with a population-averaged Oct4-GFP fluorescence of nearly 3x higher 
than cells self-renewed with LIF only at 20% O2, while 1% O2 with 2i supplementation 
achieved an increase of 2x over the 20% O2 condition with LIF only, and a 4x increase 
over cells self-renewed at 1% O2 with LIF alone (Figure 3-8A, 3-9A). 
 
To study the reversibility of the increases in Oct4-GFP expression due to 2i 
supplementation during self-renewal, cells cultured with 2i at 20% or 1% O2 were then 
subcultured with or without 2i supplementation for up to an additional 15 days at the 
same oxygen level for a total of six culture conditions. The increase in Oct4-GFP 
expression was reversed by subsequent self-renewal culture without 2i supplementation 
(Figure 3-8C,E & 9A). In all cases, the fraction of Oct4-GFP+ cells were relatively 
constant and >90% (Figure 3-9B). Therefore, changes in mean Oct4-GFP levels 
resulted from changes in the levels of Oct4-GFP expression in individual cells rather 
than in the fraction of Oct4-GFP+ cells in the populations (Figure 3-8). 
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We further characterized the cell populations that had been self-renewed under different 
conditions for 18 (Figure 3-10) and 24 days (Figure 3-11 Effects of 2i supplementation 
and culture O2 on gene expression of mESC after 24 days in self-renewing culture. by 
real-time PCR analysis. Expression of Nanog and Rex1, genes marking the naïve 
pluripotent state [52, 149], were increased in self-renewing cultures supplemented with 
2i at either O2 level, compared to the culture with the same O2 but without 2i. Markers of 
primordial germ cells Stella [150] and Blimp1 [151] were downregulated in the presence 
of 2i in self-renewal culture. Similarly, early lineage markers Fgf5 [152] and Sox17 [136] 
exhibited reduced expression in the presence of 2i during self-renewal. As a check, we 
also analyzed behaviors of Dusp6, a marker of functional ERK activity, which would be 
downregulated by MEK (Mitogen-activated protein kinase kinase) inhibitor PD035901 
[119, 153, 154], and Wnt3a, which would be upregulated by use of CHIR99021 
[120,155]; and found the expression behaviors were consistent with 2i activity. 
 
3.4.7 High oxygen and 2i use during preconditioning separately, synergistically, 
and reversibly increases subsequent differentiation to cardiomyocytes 
To study the effects on subsequent differentiation of oxygen and 2i supplementation 
during preconditioning, we self-renewed the cells as described above for 18 (Figure 
3-12) and 24 days (Figure 3-13) and performed subsequent differentiation at 20% O2 for 
all preconditioning conditions (& 13). We measured the fraction and number of MF20+ 
cells, the relative expression of cardiac associated genes cardiac α-Actin, cTnT, and 
Titin, and estimated the area fraction of wells covered by spontaneously contracting 
cells in the differentiated populations. 
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Similar trends were observed for both rounds of differentiation at 20% initiated after 18 
and 24 days of preconditioning. In cell populations differentiated after 18 days of 
preconditioning, the fraction of MF20+ cells in the population with 2i (20/2iL) was about 
26%, 2.4x higher than the control population that was preconditioned at 20% O2 without 
2i for the entire preconditioning period (20/L, 11%). The population that received 2i 
supplementation for the first 9 days, and then only LIF for the next 9 days (20/(2iL/L)) 
generated 12% MF20+ cells, which was not significantly different from the 20/L control 
population. Preconditioning at 1% O2 (1/L) reduced the fraction of MF20+ cells in the 
differentiated population compared to 20% O2 preconditioning (20/L). As in the case 
with 20% O2 preconditioning, low oxygen with 2i supplementation (1/2iL) increased the 
fraction of the MF20+ cells compared to both the 1/L and 20/L conditions, and cells 
differentiated from the 1/(2iL/L) preconditioned cells did not show a significant difference 
in the fraction of MF20+ cells from the 1/L preconditioned cells. These trends are 
corroborated by the number of MF20+ cells generated, the fraction of contracting areas, 
and gene expression analyses of cardiac genes, as well as again by the results from 
differentiation of cells preconditioned for 24 days before initiation of differentiation 
(Figure 3-13). 
 
Prior work [117, 140] has established that low oxygen during differentiation increases 
cardiomyogenesis. We hypothesize that low oxygen during differentiation acts 
synergistically with high oxygen and 2i supplementation during precondition to further 
increase cardiomyogenesis. We tested this by differentiating 20/2iL preconditioned cells 
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after 24 days of preconditioning at 5% O2 (blue bars in Figure 3-13). Indeed, low oxygen 
further increased all aspects assessed – fraction and number of MF20+, fraction of 
spontaneously contracting areas, and gene expression of cardiac-associated genes. 
20/2iL preconditioned cells produced about 31% MF20+ cells when differentiated at 5% 
O2, which was higher than the same cells differentiated at 20% O2 by 30%, 20/L 
preconditioned cells differentiated at 20% O2 by 160%.      
 
3.4.8 Fraction of MF20+ cells in differentiated populations correlates positively 
with mean Oct-GFP levels of the starting populations 
For cells differentiated at 20% O2, the fraction of MF20+ cells correlated linearly with the 
mean Oct4-GFP fluorescence of the starting (Figure 3-14) with correlation coefficients 
<R2> of 0.63 and 0.93 for cells differentiated after 18 and 24 days of preconditioning 
respectively. When data from all differentiation experiments at 20% O2 were pooled into 
a single analysis, the correlation remained strong (<R2> = 0.84) in linear form (Figure 
3-15A), and with a logarithmic dependence on the initial mean Oct4-GFP fluorescence 
(<R2> = 0.88) (Figure 3-15B). Both regressions predict >100% MF20+ cells if the 
starting Oct4-GFP fluorescence is sufficiently high, which is physically impossible. We 
therefore investigated a saturable function of the form 
𝑦 = 𝑦𝑚𝑎𝑥(1 − exp�𝐴(𝑥 − 𝑥𝑚𝑖𝑛)�)    (1)  
where y is the final fraction of MF20+ cells in the differentiated population, x the starting 
average Oct4-GFP fluorescence, ymax, is the highest fraction that can be achieved with 
a given cell line and protocol, xmin is a minimum value for a given setting on the flow 
cytometer, cells would not be considered to be Oct4-GFP+ at the initiation of 
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differentiation, and A, a scaling factor to account for differences between flow cytometer 
settings. The three parameters were fitted [156] by nonlinear regression minimizing the 
sum of the residuals in y squared. 
 
The result plotted in Figure 3-16 has physically meaningful parameter values of ymax = 
29.5%, xmin = 166.5 AU, A = -7.4x10-4, with <R2> = 0.84. In general, we would expect 
that ymax would depend on the differentiation protocol used (using low oxygen during 
differentiation for example, would increase ymax), and xmin and A would be dependent on 
the actual flow cytometer and the settings employed.   
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3.5 Discussion and future work 
High oxygen and 2i supplementation during self-renewal separately and synergistically 
increased Oct4 expression, and subsequently increased differentiation to 
cardiomyocytes. This effect was reversible with continued self-renewal by using 
appropriate oxygen modulation and elimination of 2i supplementation before 
differentiation. Differentiation to cardiomyocytes was enhanced synergistically by using 
low oxygen during differentiation. Earlier studies determined that low oxygen is best 
employed during the first 6 days of differentiation, then high oxygen subsequently [117, 
140]. Thus, oxygen conditions for synergistic enhancement of cardiomyogenesis are 
different depending on the stage of differentiation, and realization of the most 
enhancement of directed differentiation requires good control of O2 conditions to which 
the cultured cells are exposed. Future work could translate these findings to human 
ESC, as well as to differentiation protocols for other clinically relevant cell types. Other 
published studies have shown that human ESC are more similar to mouse epiblast stem 
cells (mEpiSC) than mESC, and requires ERK1/2 signaling for renewal [157], which 2i 
supplementation blocks. With the isolation of hESC that are in a naïve state more 
similar to mESC [124], it would be interesting to determine if these results can be 
directly translated to the differentiation of such hESC to cardiomyocytes.  
 
This study demonstrated a positive correlation between Oct4-GFP expression 
immediately before differentiation and the fraction of MF20+ cells in the differentiated 
populations. Recent studies [48, 128, 129] have provided a possible explanation and 
mechanism for this correlation through the action of Oct4 enhancing fate choice down 
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the mesodermal lineage during early differentiation. Future studies could include 
additional characterization of the differently self-renewed population via microarrays or 
RNA-Seq to determine transcriptome-wide differences generated in clonal populations. 
Results from such studies could direct investigations into better predictive methods for 
differentiation into other therapeutically relevant cell types. In addition, this work also 
raises new questions on the nature of preconditioning on clonal ESC populations – is 
preconditioning employing selective pressures on the population, and certain 
subpopulations favored by some culture conditions, or are all cells being affected 
equally? One possibility would be to use brainbow technology [158] or other similar 
methods to differentially mark otherwise clonal cells and to track the composition of the 
marked cells under different self-renewal conditions. Finally, to understand the role of 
Oct4 in the naïve, primed, and early differentiating ESC states, researchers could 
generate a double reporter ESC line with the distal and proximal promoter regions of 
Oct4 driving the expression of two different fluorophores in order to determine their 
relative activities in individual cells during self-renewal and differentiation. It is 
interesting to note that both Stella and Blimp1 expressions were downregulated in the 
presence of 2i in self-renewing culture, although Stella expression is associated with the 
naïve pluripotent state [53], while Blimp1 is associated with the primed pluripotent state 
[150]. Both genes are markers for primordial germ cells, and this suggests that 2i use is 
suppressing differentiation of ESC to germ cells. 
 
Prior studies on self-renewal culture of PSC have focused on the maintenance and 
propagation of cells in the undifferentiated state, and pluripotency of the cultured cells 
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was assessed by testing for the ability to differentiate into cells of all three germ layers, 
the ability to contribute to chimeras, or form teratomas. However, there have not been 
studies on the effects of self-renewal culture on the efficiency of subsequent 
differentiation to specific cell types – a focus of directed differentiation studies. Similarly, 
efforts to direct differentiation of PSC have focused on the period of differentiation, and 
have not taken into consideration the effects self-renewal conditions that have occurred 
before differentiation. This study has taken the direction of studying the effects of self-
renewing culture conditions immediately before directed differentiation of PSC, and 
found that it indeed affects the efficiency of differentiation to cardiomyocytes. 
 
These results provide a novel direction for consideration in design of directed 
differentiation protocols as different self-renewing culture conditions employed 
immediately before differentiation can affect the efficiency of subsequent differentiation 
of clonal PSC. Studies on undifferentiated culture systems of PSC would benefit from 
assessments of the efficiency of subsequent differentiation to one or more cell types of 
interest, in addition to the standard pluripotency assays, to aid future translational work. 
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3.6 Figures 
 
 
 
Figure 3-1 Effects of culture O2 in self-renewing culture on distributions of Oct4-GFP 
expression in O4G mESC. 
Oct4-GFP distributions in populations self-renewed at 20%, 5%, or 1% O2 for (A) 9 days, 
(B) 18 days, and (C) 5% or 1% for the first 9 days, then 20% for the next 9 days. 
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Figure 3-2 Mean Oct4-GFP fluorescence and fraction of Oct4-GFP+ cells from self-
renewal at different O2. 
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(A) Time course of mean Oct4-GFP fluorescence of mESC self-renewed under different 
O2 conditions. (B) Fraction of Oct4-GFP+ cells in the self-renewing populations.  
Self-renewal of mESC at low O2 reduced cell-level expression of Oct4-GFP, but does 
not increase rates of spontaneous differentiation based on the fraction of Oct4-GFP+ 
cells in the population. 
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Figure 3-3 Effects of O2 preconditioning on subsequent differentiation. 
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Cells were self-renewed at 20%, 5%, or 1% O2 for 9 days (preconditioning) before 
subsequent differentiation at 20%, 5%, or 1% O2. Each group of bars denote cells that 
have been differentiated at the same O2, with white bars representing cells that have 
been preconditioned at 20% O2, grey bars 5%, and black bars 1% O2. 
(A) Fraction of MF20+ cells in the differentiated populations. (B) Number of MF20+ cells. 
(C) Fraction of well that is spontaneously contracting. Real-time PCR analysis of (D) 
cardiac α-Actin and (E) cTnT relative to undifferentiated cells. 
Low O2 preconditioning decreases subsequent differentiation of mESC to 
cardiomyocytes. 
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Figure 3-4 Effects of O2 preconditioning on total cell number and fraction of residual 
Oct4-GFP+ cells after differentiation. 
Cells were differentiated as described in Figure 3-3 and assessed for (A) total cell 
number and (B) fraction of residual undifferentiated Oct4-GFP+ cells in the differentiated 
populations. 
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Figure 3-5 Reversibility of O2 preconditioning. 
Cells were preconditioned at 20%, 5%, or 1% O2 for 18 days, or 5% or 1% for the first 9 
days, then at 20% O2 for the next 9 days (denoted as 520, 120) before 
differentiation at 5% O2 for all conditions. *p<0.05 compared to cells preconditioned at 
20% O2. 
Preconditioning O2 [%]
20 15
20
1
20
5
Differentiation after 18 days of Preconditioning
(All differentiation performed at 5% O2)
1.2
0.8
0.4
0
E
xp
re
ss
io
n 
re
la
tiv
e 
to
 
un
di
ffe
re
nt
ia
te
d 
ce
lls
 (x
10
-3
) C Cardiac
α-Actin
*
25
20
15
10
5
0
Fr
ac
tio
n 
of
 M
F2
0+
 c
el
ls
 [%
] A
*
*
1.5
1.0
0.5
0N
um
be
r o
f M
F2
0+
 c
el
ls
 (x
10
-6
)
B
*
25
20
15
10
5
0
Fr
ac
tio
n 
of
 s
po
nt
an
eo
us
ly
 
co
nt
ra
ct
in
g 
ar
ea
s 
[%
]
D
*
*
Preconditioning O2 [%]
20 15
20
1
20
5
98 
 
(A) Fraction of MF20+ cells in the differentiated populations. (B) Number of MF20+ cells. 
(C) Real-time PCR analysis of cardiac α-Actin relative to undifferentiated cells. (E) 
Fraction of cells that are spontaneously contracting. 
The reduction of resulting cardiomyocytes differentiated from low O2 preconditioned 
mESC can be reversed by self-renewal at high O2 before differentiation, although there 
is a non-significant decrease remaining in fraction of spontaneously contracting cells for 
120 preconditioning. 
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Figure 3-6 Correlation between mean Oct4-GFP fluorescence of the starting 
undifferentiated populations and the fraction of MF20+ cells in the resulting 
differentiated populations.  
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Figure 3-7 Experimental design and nomenclature for preconditioning with O2 
modulation and 2i supplementation. 
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Figure 3-8 Effects of 2i supplementation and O2 during self-renewal on Oct4-GFP 
fluorescence distributions of undifferentiated mESC. 
Oct4-GFP distributions in populations of mESC self-renewed (A) at 20% or 1% O2 for 9 
days, at (B) 20% or (C) 1% O2 for 18 days, or at (D) 20% or (E) 1% O2 for 24 days. 
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Figure 3-9 Effects of 2i supplementation and culture O2 on mean Oct4-GFP 
fluorescence and fraction of Oct4-GFP+ cells during self-renewal. 
(A) Time course of mean Oct4-GFP fluorescence of the populations relative to cells self-
renewed continuously at 20% O2 with LIF only (20/L). (B) Fraction of Oct4-GFP cells in 
the undifferentiated populations. 
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Figure 3-10 Effects of 2i supplementation and culture O2 on gene expression of mESC 
after 18 days in self-renewing culture. 
Real-time PCR analysis of cells after 18 days of self renewal. Each group of bars 
denote cells self-renewed at the same O2. White bars represent cells in culture with LIF 
only, black with LIF and 2i, and grey with LIF and 2i for the first 9 days, and then with 
LIF only for the next 9 days with expressions relative to that of the 20/L condition. 
Genes assessed: Naïve pluripotency markers (A) Nanog and (B) Rex1; (C) marker of 
functional ERK activity (inhibited by PD0325901) Dusp6; (D) Wnt3a (stimulated by 
CHIR99021); primordial germ cell markers (E) Stella and (F) Blimp1; and early lineage 
markers (G) Sox17 (primitive endoderm), and (H) Fgf5 (primitive ectoderm). *p<0.05 
compared to 20/L; #p<0.05 compared to 1/L. 
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Figure 3-11 Effects of 2i supplementation and culture O2 on gene expression of mESC 
after 24 days in self-renewing culture. 
Real-time PCR analysis of cells after 24 days of self renewal, as described in Figure 
3-10. 
2i use during self-renewal increased naïve pluripotency markers and decreased early 
differentiation markers synergistically with high O2 and was reversible by subsequent 
self-renewing culture without 2i. 
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Figure 3-12 Effects of 2i supplementation and culture O2 on subsequent differentiation 
after 18 days of preconditioning. 
Cells preconditioned for 18 days as described in Figure 3-10 are subsequently 
differentiated at 20% O2. (A) Fraction of MF20+ cells in differentiated population. (B) 
Number of MF20+ cells. (C) Fraction of well that is spontaneously contracting. Real-time 
PCR analysis of cardiac markers (D) cardiac α-Actin, (E) cTnT, and (F) Titin, relative to 
undifferentiated mESC. *p<0.05 compared to population differentiated from 20/L cells, 
#p<0.05 compared to population differentiated from 1/L cells. 
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Figure 3-13 Effects of 2i supplementation and culture O2 on subsequent differentiation 
after 24 days of preconditioning. 
E
xp
re
ss
io
n 
re
la
tiv
e 
to
 u
nd
iff
er
en
tia
te
d 
m
E
S
(x
10
-3
)
30
20
10
0
Fr
ac
tio
n 
of
 M
F2
0+
 c
el
ls
 [%
] *
*
* *
#
A
1.5
1.0
0.5
0
N
um
be
rM
F2
0+
 c
el
ls
 (x
10
-6
)
*
*
*
*
#
B
30
20
10
0
Fr
ac
tio
n 
of
 s
po
nt
an
eo
us
ly
 
co
nt
ra
ct
in
g 
ar
ea
s 
[%
] *
None 
Detected
None 
Detected
C
6
4
2
0
Cardiac
α-Actin
*
*
#
* *
D
cTnT
40
30
20
10
0
#
*
**
*E
Titin
12
8
4
0
#*
*
* *
F
20
/L
20
/2
iL
20
/(2
iL
/L
)
1/
L
1/
2i
L
1/
(2
iL
/L
)
20
/L
20
/2
iL
20
/(2
iL
/L
)
1/
L
1/
2i
L
1/
(2
iL
/L
)
Self-Renewal Condition
110 
 
Cells preconditioned for 24 days as described in Figure 3-11 are subsequently 
differentiated at 20% (all populations) or 5% (blue bars - 20/2iL only) O2. (A) Fraction of 
MF20+ cells in differentiated population. (B) Number of MF20+ cells. (C) Fraction of well 
that is spontaneously contracting. Real-time PCR analysis of cardiac markers (D) 
cardiac α-Actin, (E) cTnT, and (F) Titin, relative to undifferentiated mESC. *p<0.05 
compared to population differentiated from 20/L cells, #p<0.05 compared to population 
differentiated from 1/L cells. 
High O2 and 2i use during preconditioning separately, synergistically, and reversibly 
increased subsequent differentiation to cardiomyocytes. This effect can be further 
enhanced by low O2 during differentiation. 
 
  
111 
 
 
Figure 3-14 Correlation between the fraction of MF20+ cells in the resulting 
differentiated populations for cells preconditioned for 18 (red triangles) and 24 days 
(blue circles) before differentiation and the mean Oct4-GFP fluorescence of the starting 
undifferentiated populations. Cells were differentiated at 20% O2. For cells 
preconditioned for 18d, <R2>= 0.63; for cells preconditioned for 24d, <R2>= 0.93, both 
from a linear least squares regression. 
  
18d preconditioning
24d preconditioning
0 1000 2000 3000
30
20
10
0
Starting Mean Oct4-GFP Fluorescence [AU]
Fi
na
l m
ea
n 
fra
ct
io
n 
M
F2
0+
 c
el
ls
 [%
]
112 
 
 
 
Figure 3-15 Linear and semi-log correlations between mean Oct4-GFP fluorescence of 
starting undifferentiated populations and the fraction of MF20+ cells in the resulting 
differentiated populations for all cells differentiated at 20% O2. 
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Figure 3-16 Model fit for correlation between mean Oct4-GFP fluorescence of starting 
undifferentiated populations and the fraction of MF20+ cells in the resulting 
differentiated populations for all cells differentiated at 20% O2.  
Model used was y = ymax(1 – exp(A(x-xmin)), where y = final fraction of MF20+ cells in 
the differentiated population; ymax = hypothesized maximum MF20+ fraction possible; x 
= starting average Oct4-GFP fluorescence; xmin = minimum fluorescence for cell to be 
considered Oct-GFP+; A = scaling factor. Fitted values: ymax = 29.5%, xmin = 166.5;  
A = -7.4x10-4. <R2> = 0.84. 
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Chapter 4 Integrative Perspective Paper: Opportunities and Obstacles 
in the Commercialization of Pluripotent Stem Cell-Based Products 
and Services  
 
4.1 Executive Summary 
The major commercialization opportunity resulting from the discovery of human 
pluripotent stem cells is their role in the production of replacement cells, tissues, and 
organs for cell therapy, with a single product potentially reaching blockbuster US market 
sizes of US$1 billion or more. However, this tremendous opportunity is equally matched 
by significant challenges, both technological and commercial. Investors and 
entrepreneurs willing to enter the market now can look to related fields of providing 
research consumables and equipment for pluripotent stem cell research or using the 
cells themselves to create research and diagnostic tools. While these markets are 
significantly smaller than that of cell therapies, there is already demonstrated profitability 
and fewer uncertainties. This also allows players to gain technologies, market 
knowledge, and the financial ability to support their moves into the cell therapy space in 
the long run. As the cell therapy market evolves from its current development phase to 
having actual products on the shelf, initial strategies taken by companies are expected 
to focus on high impact therapies, in order to attract financing with promises of high 
returns and to establish market credibility. Players pursuing this long-term goal will need 
to navigate issues of intellectual property, and regulatory and ethical challenges, before 
the oft-repeated potential of pluripotent stem cells in bringing new therapies to the clinic 
can be realized.  
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4.2 Introduction 
The discovery of human embryonic stem cells (hESCs) and their pluripotent nature 
rapidly led to widespread expectations that their contribution to human therapies and 
greatest opportunities for commercialization would arise from their potential to generate 
replacement cells, tissues, and even organs for use in regenerative medicine. The 
subsequent discovery of human induced pluripotent stem cells (hiPSCs) heralded a 
second path to the same goal, with the added advantage of significantly reducing the 
risk of rejection of the transplant, as well as sidestepping the ethical challenges 
associated with use of hESCs. Realizing this goal still requires many challenges to be 
overcome, and at this point in time, there are no FDA-approved hESC or hiPSC derived 
cell-based therapeutics commercially available, with only two hESC-based clinical trials 
in progress in the United States. The chasm between current reality and the vision is 
undeniably large and fraught with obstacles, both scientific and commercial. However, 
the commercialization options for human pluripotent stem cells (hPSCs, which include 
both hESCs and hiPSCs) are not limited to producing replacement tissues, with 
companies already bringing other hPSC-based products and services, such as 
laboratory consumables for use in hPSC research and hPSC-based tools for 
development research, drug discovery, disease modeling, and toxicology studies to the 
market. The different commercialization opportunities, associated obstacles, and 
potential business models for hPSC-based products and services are examined here. 
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4.3 Pluripotent Stem Cell Research and Diagnostic Consumables and Equipment 
As hPSC research activity grows in academic, medical, and commercial settings, so 
does demand for laboratory consumables and equipment that support such endeavors. 
Of course, much of the consumables and scientific equipment used are not specific to 
hPSC research activity, but there is a category that caters exclusively or predominantly 
to hPSC work. Examples include reprogramming ‘kits’ based on different  techniques or 
services to perform the actual work of reprogramming the client’s cells, hPSC specific 
growth factors, culture reagents, and antibodies for maintenance of pluripotency or 
directed differentiation, and testing services to evaluate the genetic stability of stem cell 
lines. 
 
The global market for such products and services was estimated to be US$883M in 
2011, growing to US$1.35B in 2015, with a 11% annual growth rate [159]. While this is 
only a small fraction of the entire US$20.5B market for the entire laboratory supply 
market in the US alone, it is certainly growing much quicker than the 0.1% annual 
growth the larger category achieved in the 5 years from 2007 to 2012, and the projected 
3.4% in the next 5 years [160]. This market is heavily dependent on research funding 
availability which feeds demand from scientists and laboratories, and the anemic growth 
in the US market over the past 5 years reflects the changes in funding availability, both 
from federal and other government sources, private foundations, and commercial 
companies.  
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Companies in this market segment include dedicated small start-ups such as Stemgent 
(Cambridge, MA), and ArunA Biomedical (Athens, GA) as well as divisions within well-
established large companies such as Life Technologies (Carlsbad, CA, soon to be 
acquired by Thermo Fisher Scientific (Waltham, MA)) and Becton Dickinson (Franklin 
Lakes, NJ). This market is considered to be mature, with well-established business 
models and a number of large operating firms with stable growth. Scale and a deep 
portfolio of products are keys to success in this model, with substantial revenue possible 
in the aggregate of small revenue streams of individual products, hence favoring large 
companies with the necessary sales and supply chain bandwidth. While smaller 
companies and start-ups may be sustainable with one or two blockbuster products, a 
typical business model for these companies would be to license their products to the 
larger companies rather than going it alone, or to be acquired [161]. An example would 
be ArunA’s agreement with Thermo Fisher Scientific to ride on their sales and 
distribution channels. Interestingly enough, the reverse has happened with the 
agreement between Pfizer and Stemgent, which will see custom reagents developed by 
Pfizer sold through the latter [162]. 
 
With the research landscape rapidly evolving, new tools and reagents come on to the 
market very frequently. Recent new products include mRNA-based reprogramming kits 
introduced in 2011, based on a 2010 publication [63]. The rapid translation of scientific 
discoveries to commercially available products and services in this market makes it 
attractive to investors and entrepreneurs. Stemgent, for example, raised $14M by 2009 
from Venture Capital (VC) firms HealthCare Ventures and Morgenthaler Ventures [163]. 
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However, the challenge is to find and occupy a niche in this crowded market with large 
established companies. 
 
Establishing a presence in this market, while not directly involved in cell therapy, can 
also be a strategy to enter the regenerative medicine market more directly. This could 
be achieved by entering collaborations with firms developing hPSC-derived cell therapy 
products in the hope that when a product does succeed, the firm would have locked in 
future demand for the consumables used in the manufacture of the cell therapy product. 
Companies looking to supply to this market will need to develop or have access to 
cGMP-certified facilities, and satisfy other FDA requirements such as those for record 
keeping, and purity and potency of product [164]. 
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4.4 Pluripotent Stem Cell-Derived Tools for Disease Modelling, Drug Discovery, 
and Toxicology 
While it is understandable that the general public’s interest in hPSC stem from their 
potential for use in replacement cell therapies, researchers and pharmaceutical 
companies are currently equally or even more interested in hPSCs as research tools for 
use in developmental studies, disease modeling, drug discovery, and toxicology [165–
167]. While this is a market with evolving business models, researchers [166, 167], 
investors [161], and industry [165, 168] are bullish on its short to medium-term 
profitability and scalability.  
 
Using hPSC’s ability to differentiate into specific adult cell phenotypes, researchers are 
now able to test drug candidates in vitro for toxicological effects, displacing current 
technologies of using transformed cell lines, primary cell lines, or animal models. The 
market for such an application alone has been estimated to be US$100M per product, 
for a total of US$500M or more [161]. However, it is hiPSC’s ability to generate adult 
cells with specific disease phenotypes, by creating hiPSC from patients with those 
diseases, and differentiating the cells into the desired cell types, that hPSCs come into 
their own as research tools. This ‘disease-in-a-dish’ concept [166] overcomes the lack 
of appropriate animal models for certain human diseases, and also enables high-
throughput screening activities not possible with use of animal subjects. Multiple 
disease-specific hiPSC lines have already been developed, such as those derived from 
patients with Type 1 diabetes, Parkinson’s disease, and Down’s syndrome [20].  
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Companies already active in this new market space also include both small and large 
firms such as iPierian (San Francisco, CA), Fate Therapeutics (San Diego, CA), 
GlaxoSmithKlein (London, UK), and GE Healthcare (Piscataway, NJ). For example, 
iPierian focusses on drug discovery platforms for neurodegenerative diseases such as 
Alzheimer’s, while GE Healthcare produces human cardiomyocytes derived from ESC 
for both toxicology studies and drug discovery. We are only beginning to see profitability 
and hence market share and leadership are in flux, with the first mover advantage for 
many diseases still not taken.  
 
That said, there are several technical challenges that need to be addressed: (1) lack of 
reliable and efficient differentiation protocols to produce certain desired differentiated 
cell types; (2) heterogeneity in differentiated cell phenotypes after differentiation; and (3) 
difficulty in recapitulating the disease in the in vitro model. For (1), both purity of the final 
cell product and amount of cells produced are still lacking. Methods to purify for the 
desired cell types continue to be topics of research [24]. As for (2), it has been reported 
that cells derived from in vitro differentiation exhibit heterogeneity in their level of 
maturity, and can thus have different phenotypes from cell to cell. Using these cells to 
assess the effect of a drug may well result in multiple false positives and negatives 
arising from a lack of consistency in the cells used [24]. Finally, as certain diseases may 
not be cell-type specific, but arise instead from interactions between different cell types 
(autoimmune diseases are a prime example), the ‘disease-in-a-dish’ may not be able to 
capture the phenotype to be studied. 
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In spite of the aforementioned technical challenges to be addressed, investors and 
entrepreneurs are positive about this market, and it has been described to have “the 
most attractive commercial opportunities for companies” in the immediate future [161]. 
Compared to providing tools for PSC-related research, developing the PSC themselves 
as research tools allows companies active in this market to move more directly into 
therapeutic applications of hPSC products. Building competencies necessary for 
success in this market, especially manufacturing-scale methods for differentiation, will 
be crucial in entering the cell therapy market. In addition, the possibility of short to 
medium term profitability in this market will allow companies to obtain favorable 
valuations from the capital markets, as well as to build a brand and financial resources 
for future expansion into cell therapies, creating opportunities for long term success. 
 
Another application of hPSCs in this arena that is further away from commercial reality 
is the concept of personalized drug discovery and testing. Instead of a ‘disease-in-a-
dish’, the possibility is now of a ‘patient-in-a-dish’ where each testing platform is 
genetically identical to the specific patient from which it was derived using iPSC 
technologies. If successfully implemented, individuals can now test the safety and 
efficacy of drugs on their own cells. However, the profitability of such a business model 
will inevitably be affected by the higher costs of having personalized testing platforms 
rather than a common one for each disease. The viability of such a service will depend 
on degree of heterogeneity in responses to the drugs being tested, and the prevalence 
of the disease. While consumers of the ‘disease-in-a-dish’ product would be commercial 
laboratories or academic researchers, it is less clear who would be paying for the 
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‘patient-in-a-dish’ service. It is likely that individuals will have to bear this cost, through 
health insurance providers, although one could imagine that the drug manufacturer may 
choose to defray part or all of the cost as a means to avail themselves of future 
recurring purchases of their therapy. In fact, some of the challenges associated with 
personalized cell therapy manifest themselves here, where there needs to be a severe 
unmet need (such as a high likelihood of a severe adverse reaction to a drug which, on 
the other hand, could be therapeutically very effective) for such a product to be 
commercially viable. 
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4.5 Replacement Cell Therapies Derived from Pluripotent Stem Cells 
We now turn to the major goal of effective, possibly personal, cell-based therapeutics 
derived from hPSCs. Despite the fact that such technologies are still in their nascent 
state, there are already those in the general public who are seeking such therapies, 
usually driven by personal circumstances, fuelled by inaccurate depictions of stem cell 
based medicine perpetuated by unscrupulous providers [169]. In reality, the FDA has 
clarified that there are currently no approved hPSC-derived cell therapies, although two 
are currently undergoing clinical trials, not including Geron’s high profile exit from the 
field after citing financial concerns [170]. 
 
To investors and entrepreneurs, the larger field of cell therapy, which is agnostic to the 
source of the cells used, is itself just a few years ahead in maturity. This rapidly evolving 
field has both ardent supporters and firm detractors [171–173]. Adding on the 
uncertainty of hPSC technology raises additional challenges, both technical and 
commercial, that need to be addressed for the successful commercialization of hPSC-
derived cell therapies.  
 
As with using hPSC-derived cells as drug discovery tools, a primary technological 
challenge is the lack of robust and scalable protocols capable of generating the desired 
cell types in the required numbers and purity. That they will be used for transplants 
raises additional constraints from the US Food & Drug Administration (FDA) such as 
additional investigations needed for those that have ex vivo contact with live non-human 
cells, on top of the already understandably strict guidelines for cell therapies [174–176]. 
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A second technological challenge is the difficulty of tracking cells after their introduction 
into the patient, and the lack of possible safeguards to reverse the procedure should 
anything go wrong [177]. The field requires major advances in biomonitoring and novel 
technologies capable of selectively removing or destroying rogue cells after 
transplantation in order to properly address safety concerns arising from the use of such 
therapeutics. 
 
Thirdly, the issue of tumorigenicity of residual, undifferentiated hPSC is a major cause 
for concern. Uncontrolled differentiation of pluripotent cells introduced into a patient, 
together with the hPSC’s ability to proliferate indefinitely, creates a safety issue unlike 
that of any other cellular therapeutic. In addition, genetic abnormalities in the hPSC 
could potentially cause the development of teratocarcinomas, which are highly 
malignant tumors with a persisting core of proliferating stem cells, raising the level of 
concern yet again [178]. 
 
A related problem arises from the use of hiPSC around the issue of safety of the 
method of reprogramming used to generate the pluripotent cells. While recent advances 
have moved away from genetic manipulations using viral vectors, favoring transient, 
non-integrative methodologies [179], difficulties in assessing the quality and efficiency of 
the reprogramming, heterogeneities in effectiveness of the techniques depending on the 
starting cell populations, and finally, concerns regarding the possible post-differentiation 
tumorigenicity of the cell products, make this a closely studied field. 
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Finally, while it is commonly recognized that allogeneic transplants using hPSC-derived 
products will necessarily have to address the immune response of the recipient, the 
assumption that autologous hPSC-derived cellular therapies will not face the same 
issues has been cast into doubt. Multiple recent publications reached conflicting 
conclusions [31, 180, 181], and this is not surprising, given that these cells have been 
exposed to factors absent in normal human physiology which may have altered their 
phenotype sufficiently to evoke an immune response. 
 
Even as researchers are tackling these technological challenges, investors, industry 
players, and entrepreneurs are finding that the rules of this new market are far from 
being written, and are contending with challenges of their own. 
 
Firstly, the patent landscape for intellectual property (IP) associated with PSCs has 
been described as a “minefield” [182], with companies interested in entering the field 
having to invest upwards of hundreds of millions of dollars on IP protection in order to 
legally operate. As a result, successful companies in this field will need to have 
comprehensive and robust IP strategies, as well as the ability to either license the 
necessary technologies from their holders, or operate around them. This issue is 
compounded by the fact that there is still no harmonization world-wide regarding the 
patentability of hPSC-associated technologies, with the example of Germany restricting 
stem cell patents [183]. The original patents issued to James Thomson and the 
Wisconsin Alumni Research Fund (WARF) covering hESC survived legal challenge in 
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the US, but with the rapidly evolving science and intense interest in the field, we should 
not expect that we will hear the definitive last word on this complex issue any time soon 
[184–186]. 
 
Looking beyond the issue of IP, business models and their associated sustainability 
have not been verified. Successful models will arise from the simultaneous evolution of 
technology and business strategy. A prior study recommended five possible strategies 
for value capture in the regenerative medicine market: (1) Orphan Designation, where 
the company focuses on a small market with unmet needs to take advantage of favored 
regulatory treatment resulting in prolonged market exclusivity, then using this 
opportunity to expand into other products with larger demands in the long run; (2) High 
Impact Therapies, where there are high unmet needs for treatments for chronic 
diseases in order to make oneself attractive for financing; (3) Platform Solution, where a 
single product serves multiple disease markets in order to build a diverse revenue 
stream; (4) Therapy Kit, for therapies with minimal cell manipulations but depend more 
on devices for administration, are for those firms with the goal of transforming into a 
device-based company; and (5) Incremental Solution, where the company introduces an 
incrementally better product than an existing offering, making use of regulators’ and 
physician’s familiarities with the product category [187].  
 
For hPSC products, it is not possible for a company to adopt strategy (5), for obvious 
reasons, and there does not seem to be current endeavors to develop products suitable 
for strategies (3) and (4). Most companies entering the field are expected to adopt 
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strategy (2), given the need to attract long term and high levels of financing, and the 
obligation to generate high returns. As the market matures in the future, newer 
companies will attempt to find their own niche by adopting (1), or gain traction using (5). 
However, this is projecting far into the future, assuming continued successes for hPSC-
derived cell therapies for a wide variety of conditions. 
 
It is also worthwhile to consider the impact of pursuing allogeneic or autologous 
products. As previously mentioned, autologous cell therapies would naturally attract 
greater operating costs due to the need for individualized processing of cells from each 
patient, while autologous treatments can take advantage of the economies of scale of 
bulk processing. This advantage is reduced with lower numbers of units produced, and 
suggests that for companies pursuing strategy (1) of targeting orphan diseases, 
autologous treatments may succeed, especially if the increased cost is lower than the 
potential gain of the autologous product over the allogeneic equivalent. A proposed 
hybrid model, where the patient requires multiple doses of the same product, can take 
advantage of economies of scale at the individual level, where the multiple doses of the 
autologous product are manufactured simultaneously. This would reduce the average 
costs of goods compared to single dose autologous products, but still suffers from a 
cost disadvantage when compared to allogeneic equivalents [161]. 
 
It is well known that there are political uncertainties and ethical controversies associated 
with the generation and use of hESCs, resulting in regulatory restrictions on their 
derivation and use in many parts of the world, including the US [188]. From the Bush 
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era restrictions to Sherley v. Sebelius, the research community has faced uncertainties 
in funding, and this may well have pushed researchers away from the field [189, 190]. 
As hESC research is still far from commercialization, a large proportion of the advances 
made have come from academic research funded through federal support. With these 
restrictions, investors may view hESC endeavors as being more risky than other 
avenues, with reduced risk sharing by the government and academia.  
 
Even hiPSCs may not be free from controversy, as questions around ownership of 
derived cell lines created from donated tissue arise, and issues of personal privacy 
around information indirectly obtained as a result of undergoing treatment become 
known, as the field advances [191]. Companies will need to remain aware of the 
sentiment of policy makers and the general public with regards to such issues and 
anticipate that their business models and strategies will need to adapt to this audience.   
 
With a US market conservatively estimated at US$1B just for a hPSC-derived product 
for Type 1 diabetes alone [161], and similar blockbuster potential expected for other 
diseases with levels of morbidity and mortality that cannot be managed with current 
therapies, it is not surprising that, despite the nascent state of the technology and 
significant risks and uncertainties, there continues to be widespread efforts to translate 
hPSC-based research into clinical applications. 
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4.6 Discussion 
While the major commercialization potential of hPSCs is that of generating replacement 
cells, tissues, and possibly organs for regenerative medicine, we are still one to two 
decades away from a first commercial product, extrapolating from the historical 
development timelines of other biotechnologies such as protein-based pharmaceuticals 
and therapeutic antibodies [192]. In the meantime, it is important to temper the 
expectations of both supporters and detractors of the field, given the far-reaching claims 
of the potential of hPSC technology, in order for the field to continue to receive 
sustainable levels of financial, regulatory, and public support [193]. Entrepreneurs and 
investors eyeing the substantial prize on the long term horizon can and already are 
making moves in the supporting market for consumables and equipment, as well as 
developing hPSC-based diagnostic and research tools to position themselves for 
successful transitions into the business of hPSC-based therapeutics [163, 165, 168]. 
 
The road to successful commercialization will not be smooth. Geron’s high profile exit 
from the cell therapy market, after the fanfare of being the first hPSC-derived cell 
therapy to reach clinical trials (a hESC-derived product for spinal cord injuries), was 
seen by many as a setback. However, after the announcement, while Geron’s share 
price dropped by 20%, the two other players with significant investments in the field, 
Advanced Cell Technology, currently the only firm with on-going Phase I trials for hESC-
derived therapies for macular degeneration, and BioTime, saw modest gains instead 
[170]. Prices of companies in the wider biotechnology field, as a whole, did not react to 
the news. This signified that investors are confident in the future earnings potential of 
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companies pursuing hPSC-based therapies. BioTime, led by Geron’s former CEO Dr. 
Tom Okarma, subsequently purchased Geron’s hPSC assets, fulfilling the underlying 
expectation that Geron’s exit was an opportunity for other players to pick up 
technologies and IP that have already been significantly de-risked by Geron’s years of 
investments [170, 194].   
 
Geron’s decision was reported to be financially driven, which underscores the large 
levels of investments and long incubation times before results can be reasonably 
expected. With the current VC exit timelines of between five and ten years, and the first 
commercial product expected to be at least twice that amount of time away, there is a 
financial gap that needs to be filled for the field to continue to move forward. 
Governments and non-profit foundations have typically filled the gap for research in this 
field, and more recently, the industry has also stepped in, many with realistic short to 
medium term strategies for sustainable operations (including those described above), 
with an eye on the long-term goal. Savvy investors and entrepreneurs who are willing to 
be patient, have the knowledge and ability to navigate the complexities of the hPSC 
markets, and the intellectual and technological capital for high impact therapies, will be 
the ones who deliver on the oft-repeated promises made at the discovery of hESCs. 
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